The Effects Of Hypothalamic Brain-Derived Neurotrophic Factor On Catecholaminergic Regulation Of Cardiovascular Function. by Cruickshank, Nicholas Christopher
University of Vermont
ScholarWorks @ UVM
Graduate College Dissertations and Theses Dissertations and Theses
2017
The Effects Of Hypothalamic Brain-Derived
Neurotrophic Factor On Catecholaminergic
Regulation Of Cardiovascular Function.
Nicholas Christopher Cruickshank
University of Vermont
Follow this and additional works at: https://scholarworks.uvm.edu/graddis
Part of the Pharmacology Commons
This Thesis is brought to you for free and open access by the Dissertations and Theses at ScholarWorks @ UVM. It has been accepted for inclusion in
Graduate College Dissertations and Theses by an authorized administrator of ScholarWorks @ UVM. For more information, please contact
donna.omalley@uvm.edu.
Recommended Citation
Cruickshank, Nicholas Christopher, "The Effects Of Hypothalamic Brain-Derived Neurotrophic Factor On Catecholaminergic
Regulation Of Cardiovascular Function." (2017). Graduate College Dissertations and Theses. 804.
https://scholarworks.uvm.edu/graddis/804
 
 
 
THE EFFECTS OF HYPOTHALAMIC BRAIN-DERIVED NEUROTROPHIC 
FACTOR ON CATECHOLAMINERGIC REGULATION OF CARDIOVASCULAR 
FUNCTION. 
 
 
 
 
 
A Thesis Presented 
 
 
by 
 
Nick Cruickshank 
 
to 
 
The Faculty of the Graduate College 
 
of 
 
The University of Vermont 
 
 
 
 
 
In Partial Fulfillment of the Requirements 
for the Degree of Master of Science 
Specializing in Pharmacology 
 
October, 2017 
 
 
 
Defense Date:  August 25, 2017 
Thesis Examination Committee: 
 
Benedek Erdos, M.D., Ph.D, Advisor 
Christopher Berger, Ph.D., Chairperson 
Wolfgang Dostmann, Ph.D. 
Frances Carr, Ph.D. 
Cynthia J. Forehand, Ph.D., Dean of the Graduate College
ABSTRACT 
 
Considerable evidence supports the claim that a hyperactive sympathetic nervous 
system (SNS) is involved in most cases of human hypertension, and therefore a more 
thorough understanding of the central regulation of the SNS may help elucidate novel 
therapeutic options. The paraventricular nucleus of the hypothalamus (PVN) is a key 
region in SNS regulation of blood pressure (BP) and heart rate (HR). Stimulation of the 
parvocellular PVN neurons has been shown to enhance sympathetic outflow and thereby 
increase BP. Brain-derived neurotrophic factor (BDNF), a modulator of neuronal activity 
is upregulated in the PVN in response to several hypertensive stimuli such as stress and 
hyperosmolarity, and previous studies from our lab demonstrated that both acute 
injections or chronic overexpression of BDNF in the PVN elevate SNS activity and BP. 
However, the BDNF-mediated hypertensive mechanisms are not completely understood. 
PVN neurons are under tonic inhibition from NTS catecholaminergic projections under 
baseline condition as indicated by significant BP increase after selective lesioning of NTS 
NE-ergic neurons. In addition, BDNF has been shown to alter NE-ergic signaling in 
multiple brain regions raising the possibility that BDNF may increase SNS activity and 
BP by interfering with NE-ergic inhibition of PVN sympathoregulatory neurons. 
Therefore, we tested the hypothesis that BDNF increases SNS activity and BP in part by 
disabling inhibitory actions of NTS catecholaminergic projections to the PVN by altering 
the expression of adrenergic receptors and NET in the PVN.  
 
 First, blood pressure was recorded using radiotelemetry in male Sprague-Dawley 
rats following bilateral microinjections of adeno-associated viral vectors expressing green 
fluorescent protein (GFP) or myc-tagged BDNF in the PVN and microinjections of 
phosphate saline buffer (PBS) or Anti-Dopaine Beta Hydroxylase (DBH)-conjugated 
saporin (DSAP), a catecholaminergic neuron-specific neurotoxin, into the NTS. Blood 
pressure was monitored both during resting conditions and during acute stress tests. A 
second group of rats received bilateral microinjections of adeno-associated viral vectors 
expressing GFP or myc-tagged BDNF in the PVN, and were sacrificed after 5 weeks. 
PVN and NTS samples were then selectively isolated using a brain punch tool, and 
expression of TH, DBH, a1a, a1b, a2a, b1, b2 receptors, and norepinephrine transporter 
(NET) was analyzed using quantitative RT-PCR. 
 
Our results show that BDNF overexpression in the PVN leads to increased 
expression of catecholamine synthesizing enzymes in the NTS. In addition, both BDNF 
overexpression in the PVN, and DSAP lesioning in the NTS increased MAP compared to 
control rats. However, combined treatment with BDNF and DSAP failed to have any 
additional hypertensive effects suggesting that BDNF treatment may abolish the 
inhibitory effect of NTS catecholaminergic projections. Lesioning the NTS 
catecholaminergic neurons didn’t appear to have a significant effect on mean arterial 
pressure response to the stress tests, although DSAP treatment appeared to decrease the 
initial heart rate response to acute stress, and this effect was most pronounced in GFP 
rats. These results indicate that BDNF overexpression in the PVN desensitizes 
sympathoregulatory neurons to inhibitory NTS catecholaminergic projections during 
baseline conditions.
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CHAPTER 1: LITERATURE REVIEW 
 
1.1. Introduction: Hypertension and Sympathetic Control of Blood Pressure 
 
1.1.1. Hypertension and increased sympathetic nervous system activity 
  Hypertension, or long-term high blood pressure (BP), is a prevalent medical 
condition that is asymptomatic, yet can lead to the development of coronary heart 
disease, stroke, and heart failure if left untreated. One of the most commonly seen risk 
factors for hypertension is old age, with one study reporting that 9 out of 10 middle-aged 
and older individuals develop elevated BP [350]. This disorder is classified as either 
primary or secondary, with most cases falling into the former category. Primary 
hypertension is caused by genetic and lifestyle factors such as obesity [178], high salt diet 
[382], major depressive disorder (MDD) [90], and stress [250]. Secondary hypertension 
accounts for a small proportion of all cases, and is caused by identifiable causes such as 
chronic kidney disease or pregnancy. More than 80% of hypertensive patients present 
with comorbidities including glucose intolerance, hyperinsulinemia, lipid disorders, and 
obesity [177, 178], which further compounds the risk for more serious cardiovascular 
diseases. There are numerous genetic markers for hypertension that have been noted to 
have small effects on BP [163], which indicates that non-genetics factors play a more 
dominant role in the progression of hypertension.  
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A meta-analysis performed in 2005 reported that approximately 26.4% of the 
global population is affected by hypertension [184], with around two thirds of the cases 
being documented in developing countries. They further postulated that approximately 
29.2% of the global population would be suffering from hypertension by 2025. While this 
disease is easily diagnosed and highly preventable through lifestyle changes [57], 
numerous reports have indicated that hypertension is inadequately controlled to goal 
levels of <140 mm Hg systolic and <90 mm Hg diastolic [45, 162, 217]. From 1999-
2004, it was found that 71.8% of individuals with hypertension are aware of it, with only 
61.4% receiving treatment, and only 35.1% of those adequately controlling their BP [75]. 
A more recent study published in 2013 reported that only ~82% of hypertensive people 
are aware of their condition, with ~52% achieving acceptable control of BP [258]. With 
such high prevalence in society, imperfect control and treatment rates, it is of the utmost 
importance for medical specialists to be able to combat this condition from as many 
different directions as possible. 
There are several anti-hypertensive drugs currently on the market that focus on 
treating the symptoms, but fail to affect the root problem. These therapeutic options 
include diuretics, calcium channel blockers, angiotensin converting enzyme (ACE) 
inhibitors, and angiotensin receptor blockers. While these drugs are effective at lowering 
BP and thereby counteracting the symptoms, they have no effect on the underlying cause 
– the elevated sympathetic nerve activity (SNA). Elevated SNA is present in most cases 
of primary hypertension [306], and therefore pharmacological treatments that target 
central circuitry may offer a novel hypertensive therapeutic option. Presently, only a few 
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surgical interventions target mechanisms that drive SNA. These include catheter-based 
radiofrequency ablation of the renal sympathetic nerves known as renal denervation, 
which has stirred up a lot of enthusiasm, but clinical trials are so far controversial on its 
effectiveness in lowering BP [194]. Another surgical procedure is known as baroreflex 
activation therapy, which involves electrically stimulating the carotid baroreceptors that 
help regulate BP and will be discussed in greater detail later, is currently being studied in 
several clinical trials [194]. Central regulation of cardiovascular functioning remains an 
underexplored area for pharmacological intervention in hypertension. The brain regions 
involved in cardiovascular regulation, alongside with the endogenous molecules that play 
relevant roles will be discussed in this paper. 
 
1.1.2. Brain Regions Involved in regulation of SNS activity and BP 
There are several brain regions that are critical to the central regulation of the 
cardiovascular system through sympathetic activation. The most relevant regions in our 
area of research are the RVLM, NTS, and PVN. The RVLM is critical for basal and 
reflex control of sympathetic activity, and receives inhibitory inputs from the caudal 
ventrolateral medulla (CLVM) and excitatory inputs from the PVN [78]. Research has 
revealed that the nucleus of the solitary tract (NTS) is the primary afferent terminal for 
baroreceptors, and thus is integral to proper baroreflex [296]. The paraventricular nucleus 
(PVN) of the hypothalamus is a key regulator of these brain regions, receiving inhibitory 
projections from the NTS and sending excitatory projections to the RVLM [78]. The 
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general circuitry connecting these regions and how they influence BP can be seen in 
figure 1. 
 
Figure 1. The central circuitry involved in sympathetic cardiovascular regulation. 
Rostral ventrolateral medulla (RVLM) neurons increase preganglionic sympathetic 
activity via projections to the intermediolateral (IML) cell column of the 
thoracolumbar spinal cord. Sympathetic outflow mediated by the RVLM is 
modulated via inhibitory projections from the caudal ventrolateral medulla 
(CVLM) or excitatory projections from the paraventricular nucleus (PVN) of the 
hypothalamus. The nucleus of the solitary tract (NTS) receives baroreceptor 
afferents and regulates sympathetic outflow from the RVLM via excitatory 
projections to the CVLM, or through inhibitory projections to the PVN. 
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The RVLM is a critical region for the basal and reflex control of sympathetic 
activity, and is implicated in abnormally elevated sympathetic activity seen in 
cardiovascular diseases such as hypertension [243].  Excitation of the RVLM produces 
increased sympathetic outflow and BP, while inhibition causes decreased sympathetic 
outflow and BP [78]. Most of the afferent inputs to the RVLM sympathetic premotor 
neurons are inhibitory in nature and come from the NTS, CVLM, and midbrain 
periaqueductal gray (PAG) area [78]. Vast amounts of research indicate that the CVLM 
plays an important inhibitory role in regulating RVLM sympathoregulatory projections to 
the intermediolateral (IML) cell column of the thoraco lumbar spinal cord via gamma-
aminobutyric acid (GABA)-ergic inhibition [67, 68, 78, 171, 295, 307]. Potential sources 
of excitatory afferents to the RVLM include the PVN [21], pontine reticular formation 
[139] and the caudal pressor area [150, 253]. Inhibitory afferent projections come 
primarily from the CVLM [78] and inhibition of the GABAergic pathway between the 
CVLM and the RVLM has been shown to increase sympathetic outflow [150]. 
The NTS is a column of grey matter in the medulla oblongata that regulates 
sympathoexcitatory signals from the PVN and RVLM [78]. The NTS receives excitatory 
afferent signals from baroreceptors located in the carotid arteries and the aortic arch 
[296]. Dendrites of efferent neurons from this region are seen in parasympathetic 
preganglionic neurons, hypothalamus, and thalamus. NTS projections decrease BP by 
sending norepinephrine (NE)-ergic projections to excite CVLM activity, which in turn 
inhibits the RVLM hypertensive activity via GABAergic projections [6, 78]. One group 
found that injections of L-glutamate into the NTS caused dose-dependent hypotension 
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and bradycardia [329]. These findings indicate that under normotensive conditions the 
NTS tonically lowers BP. While excitation of the NTS leads to decreased activity in the 
RVLM, inhibition of the CVLM through application of the glutamatergic antagonist 
kynurenic acid rescues RVLM activity and cancels out NTS-mediated inhibition of the 
RVLM. It has also been shown that NE-ergic projections from the NTS to the PVN are 
generally inhibitory in nature [80]. Silencing or lesioning these NE-ergic NTS neurons 
that project to the PVN has been shown to increase BP and HR in previous studies [80, 
96].  
The PVN is a highly integrative site for cardiovascular regulatory information  
[85, 183, 225, 326], primarily through its sympathoregulatory projections to several other 
cardioregulatory brain regions. It is located bilaterally bordering the third ventricle, is 
divided into magno- and parvo- cellular divisions [182], and sends projections to 
brainstem regions involved in sympathetic BP regulation such as the midbrain PAG, 
parabrachial region, RVLM, NTS, dorsal vagal nucleus, and the nucleus ambiguous [282, 
309]. Parvocellular neurons project to the IML and the pressor region of the RVLM, with 
approximately 30% of the spinal projecting neurons having collateral fibers to the RVLM 
[182]. Due to these varied projections, PVN neurons can influence SNA directly via a 
PVN-IML pathway, indirectly via a PVN-RVLM pathway, or both directly and indirectly 
via collaterals to the RVLM and IML [21, 65, 281, 373]. Administration of excitatory 
amino acids, or bicuculline to inhibit GABA-mediated inhibition of the PVN has been 
shown to elicit increased or decreased in RSNA [89, 137, 176], which suggests that there 
are both sympathoexcitatory and sympathoinhibitory projections from the PVN. The 
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adrenergic and NE-ergic projections to the PVN come almost completely from the A1 
and C1, A2 and C2, and A6 (locus coeruleus) cell groups [263, 264, 341]. The PVN is an 
important modulator of brainstem sympathoregulatory circuitry (Figure 2) in response to 
hypertensive stimuli such as stress, hyperosmolarity, and high salt diet [11, 58, 126, 132, 
135, 314], and as such is the major focus of this thesis. 
 
Figure 2. Visual representation of the CNS pathways controlling RSNA and the 
potential reflex pathway activated by atrial reflex stimulation leading to inhibition 
of RSNA. Retrieved from [64]. 
PVN sympathoregulatory neurons may contribute to long-term regulation of the 
SNS, particularly during cardiovascular crises such as heart failure and hypertension [12, 
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384]. Their involvement in cardiovascular regulation has been supported by a virtually 
abolished renal sympathetic response to plasma volume expansion following a lesion of 
80% of the parvocellular PVN neurons [136, 220]. It has been shown that bilateral 
inhibition of the PVN causes a marked decrease in mean arterial pressure (MAP) and 
SNA suppression [12, 380]. There is strong evidence to suggest that the PVN is essential 
for reflex reduction of RSNA in response to elevated blood volume [136, 220, 255]. 
Stimulating cardiopulmonary mechanoreceptors, which sense blood volume expansion, 
by placing a small balloon in the atriovenous junction, causes an increase in PVN activity 
[179]. Similarly activation of the PVN in anesthetized rabbits causes a similar 
cardiovascular response as is seen in blood volume expansion [89] while inhibition of 
PVN neuronal activity prevents the reflexive reduction of RSNA in response to increased 
blood volume [255]. These results have been demonstrated in a rat model as well [136], 
and combined these results indicate that the PVN is critical in reflex control of RSNA. 
 The magnocellular division of the PVN is composed primarily of oxytocinergic or 
vasopressinergic cells while the parvocellular division expresses more than 30 putative 
neurotransmitters and neurohormones including AVP, CRH, thyrotropin releasing 
hormone (TRH), and dopamine (DA) [304, 325, 326]. Magnocellular neurons project to 
the posterior pituitary and secrete AVP and oxytocin into the blood stream [182]. Recent 
evidence suggests that magnocellular neurons in the PVN play an important role in 
osmotically driven sympathoexcitation and blood pressure elevation [316]. AVP released 
from magnocellular neurons can increase PVN and RVLM neuronal activity, an effect 
which is also blocked by local application of an AVP receptor (V1a) antagonist [316]. 
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This was demonstrated in one study by showing that salt loading rats lead to significant 
increases in plasma osmolarity, MAP, and sympathoexcitation [287]. This effect was 
mitigated by pretreatment with a V1a antagonist, and as such may contribute to the 
development of hypertension [287]. Interestingly, within the magnocellular division of 
the PVN NE-ergic fibers only terminate on vasopressin-containing cell bodies while 
serotonergic and adrenocorticotropic-stained fibers terminate on oxytocinergic cell 
bodies, indicating differential synaptic control within the magnocellular PVN [182]. 
1.2. Neurotransmitters and modulators controlling sympathoregulatory neuronal 
activity in the PVN 
1.2.1. Glutamate and GABA Signaling 
Glutamate and GABA signaling is involved in the central regulation of 
sympathetic outflow, as their receptors are localized in the PVN and several other 
sympathoregulatory brain regions [22, 70, 118]. GABAergic and glutamatergic signaling 
in the PVN helps determine sympathoregulatory drive, and PVN regions involved in 
autonomic control express several glutamate and GABA receptors such as GABAA [72, 
121], NDMA and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors [143], and Glutamate Receptor 1 (GluR1) [40, 143, 349]. These 
neurotransmitters have been shown to be involved in sympathetic BP regulation, as 
microinjections of glutamate or an analog into the PVN [176] rapidly increase SNA, BP, 
and HR. Research showing that GABA receptor blockers in the PVN increase glutamate 
release [211], and that glutamate receptor blockers in the PVN prevent the pressor and 
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sympathetic response from GABA receptor blockers [54, 211] indicate that under 
normotensive conditions GABA release in the PVN tonically inhibits local glutamate 
release. Microinjections of glutamate receptor blockers into the PVN [117, 209] in 
normotensive rats have no effect on SNA, BP, or HR, but microinjections of a GABA 
receptor blocker in the PVN [211] increases SNA, BP, and HR. Microinjections of N-
Methyl-D-Aspartate (NMDA) receptor agonists in the PVN increase neuronal activity in 
the RVLM and raises BP, an effect that is attenuated by glutamate receptor blockers in 
the RVLM [373], which indicates that sympathoexcitatory glutamatergic projections 
from the PVN to the RVLM are involved in the pressor response to increased glutamate 
release in the PVN. 
 Alterations in glutamate and GABA signaling in the CNS can lead to elevated 
SNA and BP in numerous hypertension models. In spontaneously hypertensive rats 
(SHR) [43] and in deoxycorticosterone acetate (DOCA)-salt rats [228], 
intracerebroventricular (icv) injections of GABA or GABA agonists causes a significant 
decrease in BP and HR. Decreased SNA and BP from GABA agonists is similarly 
enhanced in the PVN of SHR [12], renal-wrapped hypertensive rats [232], and Dahl S 
rats on a high-salt diet [165]. Contradictory research shows that GABA antagonists in the 
PVN attenuate increases in SNA, BP, and HR seen in renal-wrapped hypertensive rats 
[232] and in SHR [209]. Taken together, these findings indicate a decreased level of 
GABA signaling in the PVN of rat models of hypertension. Other research indicates that 
glutamate signaling is increased in rat models of hypertension. Dahl S and R rats on a 
regular salt diet display no changes in BP in response to glutamate antagonists into the 
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PVN [117], but these infusions do lower the elevated BP response to high salt diet. 
Furthermore, infusion of glutamate antagonists in the PVN decrease SNA, BP, and HR in 
SHR but not in Wistar-Kyoto (WKY) rats [209]. 
 
1.2.2. Angiotensinergic Signaling 
 Within the cardiovascular regulatory nuclei (SFO, PVN, RVLM) there is an 
extensive network of angiotensin II (Ang II) and Angiotensin Type 1 receptor (AT1R) 
containing cell bodies and nerve terminals [213, 259, 358] that are independent of the 
systemic renin-angiotensin system and cause an increase in sympathetic outflow. 
Anatomical studies have confirmed the presence of AT1R in the PVN [200, 273] while 
electrophysiological studies have confirmed that PVN activity is excited by Ang II [52]. 
Ang II binding to AT1Rs stimulates a G-protein signaling pathway associated with 
protein kinase activation, which causes an increase in reactive oxygen species (ROS) 
production via activation of the nicotinamide adenine dinucleotide phosphate (NADPH) 
subunit Nox2 [357, 390]. Increased ROS levels leads to inhibition of voltage-gated 
potassium channels [391] that in turn enhances neuronal activity [357, 364] in 
sympathoregulatory neurons [390] by inhibiting GABA release onto PVN 
sympathoregulatory neurons projecting to the RVLM [208] or the IML [207]. Similar 
mechanisms exist in the RVLM as well [257, 388]. 
There are several studies that indicate Ang II signaling is a sympathoexictatory 
pathway in the PVN and RVLM. In vitro studies have shown that bathing PVN neurons 
in Ang II excites retrogradely labeled neurons of the PVN that terminate in the RVLM 
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[52]. Most neuromodulators such as NO and Ang II regulate PVN presympathetic 
neurons via indirect effects on GABAergic transmission [87, 335], as blocking AT1Rs in 
the RVLM can abolish the increased renal SNA (RSNA) caused by GABA antagonist-
mediated PVN disinhibition [328]. Along these lines, AT1R blockers in the RVLM can 
prevent the increase in BP from microinjections of Ang II into the PVN [193], while Ang 
II injections into the RVLM increase glutamate release, BP, and HR [388]. These 
findings link Ang II signaling to GABA- and glutamate-mediated changes in PVN and 
RVLM sympathoexcitatory pathways.  
Interestingly circulating Ang II is incapable of reaching the PVN given the fact 
that the PVN is protected by the blood brain barrier (BBB) and that Ang II cannot enter 
the third ventricle by way of the choroid plexus [182]. Regions of the SFO that project to 
the parvocellular PVN [237, 324, 359] are densely filled with Ang II-containing neurons 
[213, 259], and lie outside the BBB and are therefore susceptible to circulating Ang II. 
Additionally, the brain expresses all the necessary genes that encode for the essential 
components of renin-angiotensin system (RAS), including AT1R and AT2R [201, 274]. 
These SFO projections appear to use Ang II as a neurotransmitter since stimulation of the 
SFO with Ang II leads to increased Ang II release at the PVN [369]. Furthermore, Ang II 
microinjections in the SFO lead to increase BP, which is abolished by blocking AT1Rs in 
the PVN [193]. Since blocking glutamate receptors in the PVN abolishes Ang II-
mediated increased sympathetic and pressor responses in the SFO [216], Ang II-induced 
increases in neuronal activity in the SFO may be relayed to the PVN by angiotensinergic 
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projections acting on glutamatergic interneurons [109] that in turn relay the increased 
neuronal activity to presympathetic neurons.  
 Similar to the glutamate and GABA signaling pathway, the angiotensinergic 
pathway in the CNS can also contribute to sympathetic hyperactivity in a number of 
hypertension models. Increased BP seen in cold exposure [323], DOCA-salt [268], 
increased plasma aldosterone [372], and high salt diet in both Dahl S rats and SHR [155, 
156] can be prevented by icv infusions of an AT1R blocker. These findings show that 
renin signaling in the brain is important for salt-induced hypertension. Interestingly 
AT1R antagonist injections into the PVN [117] have no effect on BP in Dahl S and R rats 
on regular salt diet, but these same injections abolish the elevated BP seen in the high-salt 
diet treatment group, which indicates that AT1R activation in the PVN is correlated with 
high salt induced increases in BP. Increased AT1R activity may be explained by either 
increased synthesis of Ang II or increased responsiveness to Ang II in AT1Rs, and both 
are likely given that ACE and AT1R are substantially increased in the PVN of Dahl S rats 
on a high salt diet [358]. Local glutamate release in the PVN plays a role in regulating the 
effects of AT1R activation, as AT1R antagonists decrease BP and subsequent injection of 
a glutamate receptor antagonist further decreases BP [117].   
 
1.2.3. Catecholaminergic Signaling 
 Catecholaminergic signaling through NE and epinephrine (E) is seen throughout 
the central circuitry involved in sympathetic and neuroendocrine control of BP. There are 
limited brain regions which synthesize catecholamines, all of which help regulate the 
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SNS and include the following: A2 NE-ergic and C2 E-ergic neurons in the NTS, A5 NE-
ergic neurons in the ventrolateral pons, and A1 NE-ergic and C1 E-ergic neurons in the 
ventral medulla [74, 304]. Catecholaminergic neurons in the NTS play an important role 
in mediating sympathetic outflow from the PVN. Anatomical studies have shown that the 
NTS has a high density of NE-ergic neurons [272] that are primarily involved  in 
inhibitory projections to the PVN sympathoregulatory neurons [80, 83]. However, NTS 
NE-ergic regulation of sympathetic outflow from the PVN is a complicated issue, with 
some papers claiming that the projections are excitatory in nature [39, 53, 76, 77, 111, 
134], while others claim that the projections are inhibitory in nature [78, 80, 83, 96, 370]. 
This may be explained by NTS NE-ergic projections having different effects on BP 
depending on the situation. Most of the claims that the NTS NE-ergic projections are 
excitatory in nature come from stress studies, indicating that these neurons may tonically 
inhibit PVN sympathoregulatory neurons under baseline conditions, but during stress the 
role reverses. 
 Dopamine beta hydroxylase (DBH) is a critical enzyme for the conversion of 
dopamine into NE, and is therefore selectively seen in neurons synthesizing NE or E. 
Saporin is a ribosome inactivating protein (RIP) and a highly potent toxin due to its 
ability to interrupt formation of the universally conserved 60S subunit of ribosomes 
[321]. While saporin is a highly stable protein, it is incapable of naturally entering the 
cell and therefore must be conjugated with target-specific carrier to observe any toxic 
effects [278]. When an anti-DBH antibody is used as a conjugate to saporin, the toxin can 
enter cells that express DBH, thereby selectively destroying catecholaminergic cells. 
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DBH-conjugated saporin (DSAP) has been used in previous studies to examine the 
effects of selective lesioning of NTS catecholaminergic neurons on psychological stress-
induced increases in BP [80, 291]. In one study, it was found that DSAP microinjections 
resulted in significantly increased baseline and stress-induced MAP, indicating NTS 
catecholaminergic neurons normally tonically inhibit the MAP response to acute stress 
[80]. Interestingly there was no significant effect on baseline HR or stress-induced 
changes in HR, indicating that this mechanism is mediating by a different pathway. Rats 
given intra-PVN injection of DSAP to lesion PVN-projecting neurons showed attenuated 
peak ACTH and corticosterone following restraint stress, indicating that PVN-projecting 
NE/E neurons contribute to the generation of acute stress response [111]. However, there 
are also reports that silencing or lesioning NTS catecholaminergic neurons has no effect 
on baseline MAP [166, 167, 330].  
While there is anatomical evidence showing the presence of both a1 and a2 in the 
PVN [73], a great deal of research indicates that the a1 receptors may play a larger role 
in sympathetic and neuroendocrine regulation of the cardiovascular system. Within the 
PVN there are three different subtypes of a1 adrenergic receptors (a1A, a1B, and a1D) 
that have been identified by IHC and in situ hybridization techniques [3, 84, 95, 300]. A 
genetic analysis of the catecholamine receptor mRNA levels in the rat brain and spinal 
cord showed that a1a and a1b adrenergic receptors are highly expressed in the PVN and 
NTS [83]. A generalized genetic screening performed in 2011 for genes and pathways 
expressed in the hypothalamus in early and established hypertension revealed numerous 
genes involved with sympathetic control of BP [231]. Prominent amongst these genes 
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were Adra1b that codes for a1b adrenergic receptors, and Chga which codes for 
chromogranin, an enzyme that catalyzes the formation of catecholamine storage vesicles 
[231]. One mechanism by which stimulation of the a1 receptors in the PVN elevate BP is 
hypothesized to involve enhancement of glutamatergic synaptic inputs to the 
presympathetic PVN-spinal output neurons, which in turn increases sympathetic outflow 
[53], specifically through stimulation of presynaptic a1 adrenergic receptors [39, 76, 77]. 
The fact that glutamate is the dominant excitatory neurotransmitter in the PVN [87], 
glutamate microinjections into the PVN increase renal sympathetic activity [176], and 
that NE stimulates glutamatergic synaptic inputs to the PVN through presynaptic a1 
adrenergic receptors all lend strength to this hypothesis [39, 76, 77]. These same a1 
adrenergic receptors reduce synaptic GABA release to PVN presympathetic neurons 
when activated [53]. 
Labeling a2 adrenergic binding sites using in vitro autoradiographic techniques 
revealed high binding affinity in the PVN and NTS of both rats and humans [347]. These 
receptors generally have a hypotensive effect throughout the CNS, reducing SNA and 
BP, most commonly in the forebrain [370]. There are conflicting reports of the effect of 
a2 adrenergic receptor activation on the sympathetic regulation of BP. An argument can 
be made that a2 adrenergic receptors primary function is to lower BP based on the 
clinical uses of antihypertensive a2 adrenergic receptor agonists clonidine [100]. Other 
publications indicate that a2 adrenergic receptors may not play a large role in BP 
regulation, as administration of an a2 adrenergic receptor antagonist yohimbine into the 
PVN fails to alter the increased MAP response to histamine administration [31]. 
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However, numerous studies have shown that a2 receptors may be important in 
disinhibiting PVN sympathetic activity. NE has been shown to decrease spontaneous 
inhibitory postsynaptic currents (sIPSC) in 33% of parvocellular PVN neurons as 
mediated through a2 adrenergic receptors on presynaptic GABA receptors [133]. One 
group published data demonstrating that stimulation of a2 adrenergic receptors attenuates 
GABAergic inputs to spinally projecting PVN neurons [206], which may be involved in 
the mechanism behind the hypotensive effects of a2 activation. Other studies indicate 
that NE-induced sIPSC frequency decrease is mediated by α2 adrenergic receptors. In 
2004, Chong et al found that administration of BRL44408 (α2A-AR antagonist) blocks 
the NE-induced sIPSC frequent reduction, but prazosin (selective α2B/C-AR antagonist) 
had no effect [59]. The findings from Chong’s 2004 study confirm that the presynaptic 
GABA neurons on the PVN contain α2A-ARs [133]. 
In addition to the research linking a1 and a2 adrenergic receptors to sympathetic 
control of the cardiovascular system, there is evidence indicating that b adrenergic 
receptors may also play a role. Anatomical studies have shown that b adrenergic 
receptors are expressed in the PVN in addition to a adrenergic receptors [301]. These 
receptors appear to play an inhibitory role on PVN activity [301, 343]. Microinjections of 
fenterol (b agonist) into the PVN of SHR and WKY rats caused a decrease in BP [343]. 
Additionally, microinjections of propanolol (b antagonist) increased the spontaneous 
activity of PVN neurons [301]. A recent study reported that NE in the PVN facilitates the 
phenylephrine-induced peripheral baroreceptor reflex through its actions on b adrenergic 
receptors [356]. This was done by inducing the baroreflex with intravenous 
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phenylephrine, then administering b adrenergic antagonists or agonists into the PVN to 
observe their effects on BP. Propanolol (b adrenergic antagonist) significantly decreased 
the gain of reflex bradycardia, while isoprenaline (b adrenergic agonist) significantly 
increased the gain of reflex bradycardia [356]. However, there are contradictory findings 
as administration of guanabenz (b adrenergic agonist) in the PVN had no significant 
effect on the baroreflex [160]. 
 
1.3 BDNF and its Role in the Hypothalamus 
 
1.3.1. General Features of Neurotrophins 
 Within the CNS there is a family of growth factors known as neurotrophins 
responsible for regulating cell survival, differentiation, and growth [13]. This family of 
proteins includes nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), 
neurotrophin 3 (NT-3), and neurotrophin 4 (NT-4) [82]. NGF is most commonly 
synthesized and utilized in sympathetic and sensory target organs. BDNF, which is one of 
the primary focuses of this paper, is found throughout select brain regions, including the 
hippocampus, cortex, cerebellum, hypothalamus, and brainstem. Less is known about 
NT-3 and NT-4, as most research is currently focused on NGF and BDNF. These 
neurotrophins bind equally to the pan neurotrophin receptor 75 (p75), but have differing 
affinities for the various subtypes of tyrosine kinase receptors (Trk). 
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There are three different kinds of Trk receptors, which serve as the receptors for 
the neurotrophins. TrkA is bound by NGF, TrkB is bound by BDNF and NT-4, and TrkC 
is bound by NT-3 [82]. These receptors are largely identical intracellularly, but have 
different extracellular binding domains. There are five different domains on the 
extracellular surface, D1-D5, with D5 being the important ligand-binding domain [292, 
363]. Tyrosine kinases dimerize when both halves of the receptor are bound by their 
ligands, which indicates that neurotrophins exist as homodimers, which upon activation 
of the receptor lead to intracellular signaling cascades that regulate cell survival and 
growth, amongst other functions. These signaling molecules include Ras, 
phosphoinositide 3-kinase (Pl3K) and phospholipase C-y (PLC-y) [180]. BDNF is one of 
the more important neurotrophin in the developing and adult CNS due to its mediatory 
role in plasticity and synaptic strengthening [157].  
 
1.3.2. BDNF-Signaling in the CNS 
 
1.3.2.1. Regulation of BDNF Expression 
The BDNF gene is composed of eight 5’ untranslated exons and one protein 
coding 3’ exon, each of which is regulated by their own promoter [9] BDNF expression 
and signaling is mediated by many different stimuli, namely intracellular calcium 
signaling, increased neuronal activity, and activation of the promoter exon IV. Calcium-
induced BDNF expression has been shown to improve cell survival. This effect was 
abolished both by inhibition of voltage-sensitive calcium channels (VSCCs) and by 
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BDNF antibodies, which correlated with expression of BDNF and is reversed by 
antibodies to BDNF, which indicates that BDNF expression is mediated in part by 
VSCCs [122]. Increased calcium influx in the brain triggers phosphorylation of cAMP 
response element (CREB), an important transcription factor, which in turn binds to a 
critical calcium response element (CRE) within the BDNF gene that activates BDNF 
transcription [333]. In addition to VSCCs, glutamate receptors such as the NMDA 
receptor are also implicated as a stimulus for BDNF transcription [376-378]. Therefore, 
neuronal activity stimulates the initiation of BDNF gene transcription, which is regulated 
by elevation of intracellular Ca2+ concentration via the NMDA receptors or the L-type 
voltage-gated calcium channels [378]. This activity- and Ca2+- dependent transcription of 
the BDNF gene occurs predominantly through exons I and IV, with the promoter on exon 
IV being highly sensitive to elevated Ca2+ levels with three different Ca2+-response 
elements (CRE) [334, 386, 387]. 
In mature neurons, the epigenetic mechanism by which neuronal activity 
differentially controls BDNF promoters is believed to include H3K27 acetylation via 
CREB/CBP and polycomb de-repression [265]. H3K27 acetylation is known to be 
important for BDNF mRNA expression mediated through promoters II and IV [265]. 
Indeed promoter IV has been shown to be an important site for promotion of BDNF 
mRNA transcription, and defects here have been associated with depression-like behavior 
in mice [299], similar to decreased BDNF levels in the hippocampus seen in depressed 
patients [98]. When phosphorylated, cyclic AMP (cAMP) response element (CREB)-
binding protein (CBP) kinases translocate to the nucleus and recruit the transcriptional 
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co-activator CBP with histone acetyl transferase activity [265]. Polycomb repressive 
complexes (PRC) are required to silence developmental regulator genes to ensure 
expression occurs only at later stages of stem cell differentiation [42, 199]. Receptor for 
activated C kinase 1 (RACK1) is a scaffolding protein important in cAMP pathways, and 
research shows that the association of RACK1 with β-actin participate in the cAMP-
dependent regulation of BDNF transcription through promoter IV [254]. 
Interestingly the BDNF gene contains multiple promoters that can be specifically 
regulated under different conditions to generate different mRNAs that are tissue- and 
stimulus-specific [280, 337, 338]. In vivo BDNF transcription upregulation has been 
demonstrated during induction of LTP or associative learning [270], and in the visual 
cortex when stimulated by light [51]. Neuronal activity also regulates the temporal and 
spatial expression of different BDNF isoforms [23, 262]. One of these conditions is 
contextual fear, which has been shown to increase H3 acetylation at the BDNF promoter 
IV, thereby increasing total BDNF mRNA expression [224]. Additionally, impaired fear 
extinction has been shown in mice lacking the promoter IV region, indicating that 
increased BDNF transcription is involved in this behavioral paradigm [148]. Defeat stress 
has been shown to downregulate transcripts of BDNF from promoters IV and VI which 
was accompanied by increased H3K27 demethylation, resulting in a marked decrease of 
BDNF mRNA levels [342]. Chronic stress experiments in rats have been shown to 
increase BDNF mRNA expression in the BNST [132]. Increased BDNF mRNA 
expression is also seen in the parvocellular PVN, the lateral hypothalamus, and select 
regions of the pituitary gland in response to acute (2 hour) or repeated immobilization 
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stress [314]. Additional hypertensive stimuli such as high salt intake and obesity have 
also been shown to increase BDNF mRNA expression [58, 355].  
 
1.3.2.2. BDNF Transport and Secretion 
 BDNF is transported to secretion sites by motor protein complexes of polarized 
neurons, although the exact organelles involved in the BDNF-containing vesicle secretion 
is controversial [5]. This transport and secretion has been observed in axons and dendrites 
of cultured cortical and hippocampal neurons [4, 169, 235], and has also been observed in 
knock-in mice expressing Myc-tagged BDNF at the presynaptic terminals of the adult 
hippocampus [92]. Fluorescent protein-tagged BDNF was predominantly seen in the 
Golgi apparatus of dendrites in cultured hippocampal neurons and adult rat hippocampus, 
indicating local BDNF secretion pathways and local protein translation in the dendrites 
[151, 152]. While the exact BDNF transport mechanism remains poorly understood, 
injections of radioactively labelled BDNF have shown that BDNF transport is both 
retrograde and anterograde in the CNS [4, 15, 48, 290, 319]. Anterograde transport of 
BDNF that has been reported on in the visual system [48, 319] is microtubule-based and 
involves motor protein kinesin and coordinator dynactin [195]. Quantitative 
autoradiographic electron microscopy has shown that BDNF is retrogradely transported 
in motor neurons, wherein it is released from postsynaptic sites and internalized by 
afferent presynaptic terminals [290]. 
 Not only is the Golgi apparatus implicated in BDNF secretion, evidence shows 
that the cell soma, axon and dendrites can secrete BDNF in a neuronal activity-dependent 
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manner [99, 203]. More specifically, Ca2+ influx through inotropic glutamate receptors 
or L-type VGCCs followed by signal amplification through Ca2+-induced Ca2+ release 
from the ryanodine receptors is required for BDNF secretion [203]. While activation of 
Trk receptors and Na+ channels may not be required, activation of CaMKII and PKA are 
required for secretion [99, 189]. Research implicates two proteins in the vesicle fusion 
step of BDNF secretion: Synaptotagmin IV [86] and Ca2+-dependent activator protein 
for secretion 2 (CAPS2) [297, 312]. Synaptotagmin IV negatively regulates BDNF 
section in the hippocampus at both the axons and dendrites [86], while CAPS2 enhances 
the efficiency of activity-dependent BDNF secretion [312]. 
 
1.3.2.3. The Role of BDNF in Development, Learning, and Memory 
One of the most well-established functions of BDNF is the regulation of synaptic 
plasticity, which refers to the ability of synapses to adaptively strengthen or weaken in 
response to increases or decreases in their activity. At a cellular level, this means that 
BDNF interacts with neurons and muscle cells to potentiate excitatory neurotransmitter 
release to the hippocampus [175, 204], and to induce structural changes in neurons by 
increasing synapto- and dendridogenesis [33, 374], promoting axonal growth, and 
dendritic arborization [4]. BDNF-induced axon growth is initiated by TrkB-dependent 
local elevation and stabilization of cAMP/PKA activity, an essential step demonstrated in 
hippocampal neurons [56, 311]. BDNF/TrkB-induced Akt phosphorylation reduces GSK-
3 activation, which causes a decrease in active collapsin response mediator protein-2 
formation, which plays a critical role in microtubule formation during axon growth [318, 
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375]. Numerous studies have shown that BDNF concentration gradients produced by 
BDNF-containing micropipettes can cause the axonal growth cone to turn towards the 
higher BDNF concentration in a cAMP-dependent mechanism in cultured Xenopus spinal 
neurons [61, 318]. Studies on dendritic arborization have revealed that BDNF 
overexpression in pyramidal cells increases the length and number of apical dendrites in 
rats [365], an effect that is mediated by MAP kinase and PI3 kinase activation [93, 240]. 
In addition to axonal elongation and dendritic arborization, BDNF plays a role in 
synapse formation and stabilization [354] in the developing and mature CNS. TrkB KO 
mice show a significant decline in hippocampal synapse structures, and selective TrkB 
KO in the cerebellum results in reduced inhibitory synapses [233]. Both excitatory and 
inhibitory synapse formation, and increased excitatory synapse numbers can be promoted 
by exogenous application of BDNF in rat hippocampal neurons [345, 353]. Synaptogenic 
function of BDNF and TrkB has been shown in inhibitory GABAergic connections in the 
visual cortex [158], cerebellum [288], and hippocampus [234]. BDNF has been shown to 
modulate synaptic efficacy and plasticity, as is seen in both long-term potentiation (LTP) 
and long-term depression (LDP) [128, 222]. Excitatory synaptic efficacy is enhanced by 
BDNF through the modulation of NDMA receptor function [212, 322] and ion channels 
including Na+ [202], K1.3 [344], and TrpC3 channels [210]. BDNF has also been shown 
to promote membrane insertion of NDMA [47] and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) [164] receptors in postsynaptic cites. Interestingly 
BDNF has variable effects on GABA receptors in a bi-directional manner. Presynaptic 
GABA transmission was suppressed by acute and chronic BDNF administration into 
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hippocampal slices [38, 115], and potentiated in cultured hippocampal neurons [24]. 
Additionally, BDNF potentiation [172] and suppression [332] has also been shown in 
postsynaptic GABAergic currents.  
The role of BDNF in learning and memory formation has been shown in several 
studies [69, 339], as it is involved in the conversion of short-term memories into long-
term memories in various behavioral paradigms [14, 223, 284]. Disruption of BDNF 
expression leads to severe impairment in spatial memory and learning. This has been 
shown using many different methodologies, including antisense oligonucleotides [244], 
BDNF KO mice [214], and anti-BDNF antibodies [247]. BDNF has also been implicated 
in the facilitation of LTP, the persistent strengthening of synapses critical for memory 
formation and long-term memory consolidation [36, 223, 269]. Specifically, BDNF 
mRNA levels are reportedly increased with the induction of LTP [266]. BDNF has been 
shown to be essential to LTP, as BDNF KO mice show impaired LTP in hippocampal 
slices, a deficit that can be reversed by application of BDNF [269, 279]. Behavioral 
manifestations of deficient LTP in BDNF KO mice models includes impaired novel 
object recognition and spatial learning in the Morris water maze, and reduced conditioned 
fear extinction, which implies a critical role of BDNF in hippocampal cognitive function 
and memory extinction [140]. Mutational analysis of the TrkB receptor reveals that 
phosphorylation of the PLC-y-binding site in the hippocampus is essential for optimal 
LTP [242].  
Perhaps one reason why BDNF is so vital to LTP is that it generally promotes 
excitatory neurotransmission. Indeed, nanomolecular concentrations of BDNF in the 
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hippocampus, cortex, and cerebellum have been reported to lead to neuron excitation 
[173]. This is generally achieved through the promotion of glutamate activity through the 
NMDA receptor [37], and the γ-aminobutyric acid (GABA) receptor during development 
when GABA is excitatory rather than inhibitory [44, 332]. Intriguingly, BDNF causes 
TrkB-dependent suppression of AMPA receptor-mediated synaptic transmission [317]. 
While mature BDNF facilitates LTP, research has shown that pro-BDNF primarily 
functions during LTD following low frequency stimulation (LFS). Reports show that pro-
BDNF enhances NDMA receptor-dependent LTD in the hippocampus through p75NTR 
activation [367]. This mechanism appears to be independent of NDMA or AMPA 
receptors, as NMDA receptor-dependent LTP and LTD were unaffected in p75NTR KO 
mice [367]. Given that activation of p75NTR negatively affects dendrite complexity and 
spine density in hippocampal neurons [379], pro-BDNF is likely to modulate neurite 
morphology and synaptic plasticity in a manner that opposes BDNF function.  
 
1.3.3. Hypothalamic Actions of BDNF 
 
1.3.3.1. The Role of BDNF in Hypothalamic Sympathetic BP Regulation 
Hypertension can be caused by many different internal and external conditions. 
Stress is a well-known cause of hypertension, and it has been shown that industrial 
workers with higher job strain had a 2.2 fold cardiovascular mortality risk compared to 
their low job strain counterparts [186]. Acute and chronic stress have been shown to 
increase BDNF mRNA levels in the PVN (Figure 3), indicating that BDNF is a stress-
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responsive intracellular messenger and may be an important component of the stress 
response [50, 132, 285, 314]. Using in situ hybridization, BDNF mRNA was shown to be 
present in the PVN, and that acute or repeated immobilization stress resulted in increased 
expression [314]. Given that BDNF and TrkB mRNA was seen in the PVN in response to 
stress, it is possible that BDNF acts as a local paracrine or autocrine mediator in the 
hypothalamus [314]. Rats exposed to a 7-day chronic stress paradigm demonstrated a 
dramatic increase in BDNF levels in the PVN [132]. Not only does stress cause an 
increased BDNF mRNA expression in the PVN, but hypertonic saline injections also do 
so in the magnocellular and parvocellular PVN [50]. However, the exact mechanism 
underlying how stress increases BDNF in the PVN remains poorly understood.  
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Figure 3. BDNF mRNA expression in the PVN detected by in situ hybridization. 
Photomicrographs of emulsion-dipped hybridized hypothalamic sections with the 
specific [35S]-labeled antisense BDNF probe in control (unstressed) adult male rats 
and after 15, 60 and 180 min of immobilization stress application. Scale bar=200 
µm. Retrieved from [285]. 
 Recent work in our laboratory has been focused on analyzing the effects of BDNF 
signaling in the PVN on sympathetic regulation of BP. In our 2015 study, cardiovascular 
data was gathered using radiotelemetry in Sprague-Dawley (SD) rats following bilateral 
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PVN microinjections of viral vectors expressing either BDNF or green fluorescent 
protein (GFP). The results showed for the first time that increased BDNF mRNA 
expression, or acute BDNF injections, in the PVN leads to increased BP and HR under 
baseline conditions [102, 305]. BDNF was also shown to modulate the cardiovascular 
responses to acute stress, wherein water stress- and restraint stress-induced increases in 
MAP were significantly reduced in BDNF rats, while HR responses to acute stress were 
unaffected by BDNF treatment [102]. The elevations in BP, HR, and sympathoexcitation 
caused by BDNF overexpression in the PVN are mediated in part by modulation of 
angiotensin signaling as BDNF rats expressed a significantly higher level of AT1R, and 
inhibiting the AT1Rs with losartan caused a significant reduction in MAP and HR [102]. 
Our laboratory has also studied the effects of short-term increases of BDNF levels 
in the PVN, the results of which demonstrate that BDNF injections lead to short-term 
elevations in BP that is mediated by increased sympathetic nerve activity [305]. 
Furthermore, infusion of the AT1R antagonist losartan into conscious rats attenuated the 
BDNF-induced increase in MAP, an effect that was also seen in anesthetized rats 
following pretreatment with losartan [305]. Peripheral blockade with hexamethonium 
reduced baseline MAP, and lowered average and peak BDNF-induced increases in MAP 
to a similar level as rats pretreated with losartan [305]. However, unlike pretreatment 
with losartan, the HR response to BDNF was abolished by hexamethonium [305]. These 
results indicate that Ang II-AT1R signaling is a potential mediator of the acute BP 
response to BDNF acting within the PVN [305]. However, other mechanisms may be 
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involved and further research is needed to elucidate the role of catecholaminergic and 
glutamatergic signaling in the response to BDNF. 
Catecholamines play a critical role in the sympathetic control of the 
cardiovascular system, and BDNF may be an important regulator of catecholamine 
synthesis and secretion. In the rat hypothalamus, BDNF increases NE uptake and 
decreases its stimulated release through interactions with the TrkB receptor [293]. 
Additionally, homozygous BDNF mutations have been shown to produce profound 
reductions of NE within the hypothalamus [94]. A study examining the effects of BDNF 
on survival and regulation of catecholaminergic neurons found that BDNF treatment 
resulted in a dose-dependent increase in the number of TH-positive neurons, dopamine 
content, and dopamine uptake activity [161]. In brain striatal slices, the interaction 
between BDNF and TrkB increased the evoked release of dopamine through the 
stimulation of PI3K and MAPK activities [127]. There are conflicting findings with 
regards to BDNF effects on NE levels, as in vitro studies of neural crest cells showed that 
neurotrophins did not modify NE uptake in these cells [381]. Both increased expression 
of BDNF in the PVN [102] and lesioning NTS NE-ergic projections to the PVN using 
DSAP [80] have been shown to increase BP. However, the possibility that BDNF 
regulates cardiovascular function by modulating catecholamine signaling in the PVN has 
not yet been studied. 
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1.3.3.2. BDNF-Mediated Regulation of the Hypothalamic-Pituitary-Adrenal (HPA) Axis 
The HPA axis is a major neuroendocrine pathway associated with internal or 
external stress response, and corticotropin releasing hormone (CRH) is an important 
regulatory hormone in this pathway [145]. Peptidergic neuroendocrine neurons located in 
the medial parvocellular region of the PVN that release CRH and arginine vasopressin 
(AVP) (Figure 2) acts as an obligate factor in the subsequent release of ACTH from the 
anterior pituitary in most organisms [17, 145, 239]. Co-secretion of CRH and AVP from 
the median eminence [18, 362] into portal circulation in response to stressful stimuli 
[276] act synergistically on ACTH secretion from the anterior pituitary [123]. ACTH 
secreted from the anterior pituitary travels through the systemic circulation to the adrenal 
cortex where it triggers release of glucocorticoids, which are essential to stress 
adaptation. Glucocorticoid receptors (GRs) are highly expressed in the PVN and are co-
localized with CRH [215, 346], and are involved in negative feedback regulation of the 
HPA axis during times of stress when plasma glucocorticoid levels are high [286]. AVP 
has little effect on ACTH release, though it can greatly amplify CRH’s ability to 
stimulate ACTH release [123]. AVP synthesis and secretion from CRH neurons may be 
important in the HPA axis adaptation to chronic stress [141, 142], and has been shown to 
be important to acute stress response as well [360]. The PVN is the key nucleus in HPA 
axis regulation given that it starts the cascade, and indeed appears to have unique 
plasticity capacities to meet these physiological stress stimuli [124] which allow cells to 
adapt to future stressors [28, 29].  
 32 
 
Figure 4. Plasticity (represented by *) in the HPA axis following chronic stress. 
Retrieved from [145]. 
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While both AVP and CRH modulate ACTH release from the anterior pituitary 
gland, CRH is more obligatory for HPA axis activation as deletion of the CRH gene 
blocks basal and stress-induced release of ACTH [248]. The mechanism by which CRH 
triggers the release of ACTH involves binding to the corticotropin-releasing hormone R1 
receptors (CRHR1), which in turns causes activation of adenylate cyclase [7]. AVP has 
the capacity to compliment CRH-mediated ACTH release by binding to the AVP1B 
receptors [283], which allows for a dynamic range of corticotropin response following 
PVN stimulation. A subset of PVN CRH neurons project centrally and have behavioral 
regulation functions, as parvocellular PVN lesions reduce anxiety-like behavior [146]. 
Optogenetic inhibition of PVN CRH neurons leads to increased anxiety-like behavior in 
mice and stimulating these neurons achieves the opposite effect [116], which indicates 
that PVN CRH neurons contribute both to neuroendocrine and behavioral responses to 
stress.  
In addition to synthesis and secretion of CRH, parvocellular CRH neurons in the 
PVN have the capacity to express other neuropeptides such as Ang II, cholecystokinin, 
and neurotensin [327]. They also have the capacity to release glutamate [154], which may 
influence the release of neuropeptides at the level of the neurovascular junction in the 
median eminence [153]. Indeed, local glutamatergic signaling may be important in HPA 
axis control due to research showing that inhibition of glutamate receptor 5 (GluR5)-
containing kainite receptors in the median eminence reduces stress-induced ACTH 
release [103]. Fast feedback, or GR-mediated negative feedback of the CRH neurons, is 
most likely mediated by non-genomic signaling at the cell membrane in response to acute 
 34 
stress [91, 336]. Genomic feedback of CRH neurons would likely occur at longer post-
stimulation latencies, and may be involved in glucocorticoid-mediated inhibition of CRH 
and AVP gene expression following adrenalectomy [302, 303]. Finally, glucocorticoids 
may also signal through mineralocorticoid receptors (MR), as research shows that 
occupation of the MR may be required during certain kinds of stress [62], and even 
though there is MR expression in the PVN [20] its role in local regulation of HPA axis 
function remains to be explored. 
Numerous reports have shown elevated BDNF mRNA expression in the PVN in 
response to stress [126, 132, 313, 314], and that BDNF is involved in the initiation of the 
HPA axis through regulation of hypothalamic hormones [126, 170]. Immobilization 
stress results in increased BDNF mRNA expression in the hypothalamus and pituitary 
[125, 285], both of which are regions vital to the HPA axis. In a study of BDNF effects 
on CRH and AVP synthesis and secretion, icv BDNF injections induced a gradual 
increase in CRH mRNA signal and a progressive decrease in AVP mRNA signal in the 
parvocellular and magnocellular PVN [126]. Using in situ hybridization, they also 
showed that BDNF, CRH, and AVP were co-localized in the parvocellular and 
magnocellular PVN after varying lengths of immobilization stress [126]. These results 
support findings from previous studies which showed co-localization of BDNF with CRH 
[315], CRH with AVP [361], and BDNF with AVP [11]. The role that BDNF plays in the 
HPA axis may occur in two steps, first initiating a rapid release of CRH from the PVN, 
and second in the reconstitution of CRH stores. Evidence for this comes from the studies 
showing that BDNF infusion into the PVN leads to a significant drop in CRH content 
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with an increase in circulating ACTH and glucocorticoids [126]. Other studies claim that 
BDNF may play a role in reconstituting necrohormone stock due to its ability to stimulate 
neuropeptide synthesis in hypothalamic cultured neurons [218, 219]. 
 
1.3.3.3. BDNF-Mediated AVP Secretion and Osmoregulation 
 Blood volume regulation is dependent on the appropriate solute concentration in 
plasma (osmotic homeostasis) and plasma volume (volume homeostasis), and these 
factors are dependent on the perception of thirst and the ability to synthesize and secrete 
the antidiuretic hormone AVP from magnocellular neurons in the PVN in addition to 
many other influencing factors [198]. In fact, there is a direct correlation between 
circulating AVP concentrations and plasma osmolarity [97]. The mechanism by which 
AVP increases plasma volume involves induction of cyclic adenosine monophosphate 
(cAMP) and the translocation of aquaporin-2 water channels to the plasma membrane of 
tubular epithelial cells, which allows for water reabsorption [310, 348]. Interestingly, 
when plasma osmolarity rises, there is a behavioral effect wherein the animal is induced 
to drink shortly after the release of AVP [198]. While the PVN is somewhat 
osmosensitive [149, 261], most osmoregulatory input comes from afferent projections 
from other brain regions. The organum vasculosum lamina terminalis (OVLT) and the 
median preoptic nucleus are predominant afferent projections whose importance in 
promoting AVP secretion and the thirst response to hyperosmolarity has been 
demonstrated in lesion studies [41, 238]. The SFO may also contribute to 
hyperosmolarity-induced AVP secretion from the PVN via direct projections to the PVN 
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or the OVLT using Ang II as a mediator [41, 110, 191, 331]. While the forebrain nuclei 
tend to carry osmoregulatory information to the PVN, brainstem regions such as the NTS 
tend to carry equally important information involved in AVP secretion, namely 
baroregulatory information associated with hypovolemia and hypotension [41, 198]. The 
baroreceptor information projects to the NTS via the vagus and glossopharyngeal nerves, 
and then to the PVN through ascending catecholaminergic pathways [198].  
 There are numerous papers that claim BDNF stimulates AVP secretion in 
response to hyperosmotic or high salt stimuli. It has been widely reported that osmotic 
stress increases BDNF mRNA in the supraoptic nucleus (SON) and the PVN [11, 50]. 
Following i.p. injections of hypertonic saline solution, IHC analysis of the SON and PVN 
revealed that BDNF mRNA expression preceded AVP increase in these regions, 
indicating that BDNF may act as an autocrine or paracrine agent in the regulation of AVP 
secretion [11]. Examining the expression patterns of BDNF and AVP following 
immobilization stress revealed that there is a close temporal correlation between stress-
induced hypothalamic BDNF increase and AVP mRNA variations, which indicates that 
acute stress can also initiate the release of AVP [126]. Additionally, in vitro study of 
isolated hypothalamic cell culture revealed that BDNF positively modulated AVP release 
[246]. It is known that osmotic stress leads to chemical and morphological changes in the 
PVN and SON [138], therefore it is possible that early increase in BDNF mRNA 
expression may serve to prepare neurons for additional metabolic change induced by 
osmolarity changes [236]. 
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1.3.3.4. Involvement of BDNF in Hypothalamic Regulation of Appetite and Metabolism 
The hypothalamus’s role in food intake control has been noted since the 1940s 
when Hetherington and Ranson showed that localized lesions of the hypothalamus result 
in obesity [147]. Interestingly later research demonstrated the opposite effect of anorexia 
and weight loss by lesioning the lateral hypothalamus [147]. The discovery of leptin in 
the 1990s clarified how the hypothalamus regulates food intake [383]. Leptin is a “satiety 
hormone” responsible for inhibiting hunger that orchestrates the neuroendocrine 
adaptations to nutrient availability, and as such the plasma concentration of leptin can be 
used as an indicator for body fat stores [8, 27, 120, 174, 260, 308]. In other words, 
nutrient abundance leads to increased leptin secretion and subsequently decreased 
appetite and increased caloric disposal, whereas nutrient insufficiency results in the 
opposite. High levels of leptin lead to increased expression of weight loss promoting 
genes such as a-MSH and CART, while low levels of leptin lead to increased expression 
of genes that promote weight gain and reduced energy expenditure such as agouti-related 
protein (AGRP) and NPY [88]. 
The arcuate nucleus in the mediobasal hypothalamus is the primary site of action 
for leptin via two separate and functionally opposing groups of neurons usually identified 
as proopiomelanocortin (POMC) neurons and NPY / AGRP neurons, the 
phosphatidylinositol 3-kinase (Pl3K) signaling pathway and by phosphorylating signal 
transducer and activator of transcription 3 (STAT3) [30, 198, 385]. POMC neurons, also 
known as a-melanocyte stimulating hormone (a-MSH) and cocaine- and amphetamine-
regulated transcript (CART) neurons, produce many hormones involved in feeding 
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behavior, including melanocyte-stimulating hormone (MSH), ACTH, and b-endorphins 
[241]. Type 4 melanocortin receptor (MC4r) knockout (KO) animals, or humans with 
mutations interfering with MC4r functioning generally develop severe obesity syndrome 
[104, 159, 168, 192]. The weight gain typically seen when aging may be explained by a 
loss of tone in the melanocortin signaling system [130, 245]. Taken together these results 
indicate that melanocortin signaling may be the predominant regulatory system involved 
in appetite and satiety [198]. On the other hand, cancer cachexia may be prevented by the 
administration of melanocortin receptor antagonists [229, 366]. 
NPY/AGRP neurons are also involved in feeding behavior, as injecting AGRP or 
NPY into the brain caused an increase in food intake [19]. These neurons send 
monosynaptic projections to near identical regions of the hypothalamus as POMC 
neurons, which integrate the signals before relaying them to other brain regions 
associated with feeding behavior, energy expenditure, and hypophysiotropic function [8, 
27, 174, 308]. There are reciprocal connections between the arcuate nucleus NPY/AGRP 
neurons and the a-MSH/CART neurons which increases the complexity of the system 
[66]. AGRP has been shown to antagonize melanocortin receptors, and so periods of low 
leptin concentration also result in lowered melanocortin due to a rise in AGRP [256, 
260]. Hypophysiotropic thyroid releasing hormone (TRH) neurons in the medial 
parvocellular PVN receive direct projections from NPY/AGRP and a-MSH/CART 
neurons to alter the set point at which circulating thyroid hormone inhibits TRH [105-
108]. The anterior and ventral parvocellular PVN may also be involved in other actions 
of leptin, such as feeding regulation and/or energy disposal, as both subdivisions receive 
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high density of a-MSH and AGRP axons [131, 320]. Anterior parvocellular PVN neurons 
may be involved in behavioral manifestations of feeding through their projections to the 
limbic system [225, 294]. Ventral parvocellular PVN neurons may be involved with 
regulation of energy disposal through the projections to the brainstem and spinal cord 
[294, 304, 325]. 
Numerous studies have linked BDNF to body weight and food intake regulation, 
indicating that one of BDNFs functions in the PVN is to regulate body weight and food 
intake [147, 197]. BDNF injections into the PVN reduced high-fat diet-induced obesity 
and metabolic syndrome-like measures, with high body fat animals exhibiting a more 
significant response to BDNF [355]. It is generally understood that BDNF induces weight 
loss in rats through a mechanism involving appetite suppression [271]. BDNF has 
downstream mediator effects on leptin signaling pathways, as leptin injections into the 
ventromedial hypothalamus lead to increased expression of BDNF mRNA, which is 
regulated by the nutritional state and MC4r signaling [190, 371]. Studies of heterozygous 
BDNF+/- mice, which would display lower than normal BDNF expression, exhibited 
statistically significant increases in body weight and food intake relative to wild type 
controls [226]. In a similar study of heterozygous disruption of various neurotrophins, 
only BDNF+/- mice showed a significant increase in body weight and food intake [185]. 
One mechanism by which BDNF induces decreased body weight and food intake is 
through the upregulation of CRH and activation of CRH type-2 receptors in the PVN, 
which indicates that long-term BDNF exerts anorexic and metabolic effects through a 
CRH-mediated pathway [340]. Findings from our laboratory suggest that BDNF in the 
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PVN causes weight loss. Increased BDNF expression in the PVN significantly increased 
nighttime physical activity levels, and significantly reduced body weight compared to 
GFP treated rats and compared to pre-injection body weight [102]. Although losartan 
treatment was able to prevent the BDNF-induced weight loss, body weight in BDNF + 
losartan groups was still significantly lower than in GFP rats [102]. The results indicate 
that BDNF-induced changes in body weight are mediated in part by changes in 
angiotensin signaling [102, 305]. 
1.4. Perspectives 
 The topics discussed in this literature review indicate that BDNF may act both as 
an acute regulator in the PVN mediating acute-stress induced BP elevations, and as a 
chronic regulator of PVN neuronal function by inducing chemical and structural changes 
in response to the hypertensive stimuli such as chronic stress, high salt diet, and obesity. 
The mechanisms may involve alterations in NMDA and GABA function [212, 234, 322, 
345, 353], interaction with AngII signaling [102, 305, 389, 391], or potentially altering 
NE-ergic signaling [112, 144, 277]. Hippocampal studies have revealed that BDNF 
acutely stimulates phosphorylation of NMDA receptors [212, 322], and chronically 
through regulating the density of excitatory and inhibitory synapses [1, 234, 345, 353]. 
Previous publications from our laboratory have demonstrated that BDNF-induced 
increases in MAP are regulated by AngII signaling, as pretreatment with an AT1R 
antagonist abolished the BP response to acute BDNF injections [305] and chronic 
overexpression of BDNF resulting from viral vector injection caused significant increase 
in AT1R expression compared to control [102]. Catecholaminergic signaling has also 
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been shown to be affected by BDNF. Expression of adrenergic receptors is regulated by 
BDNF, as TH-positive neuronal cell count increased in response to BDNF [161], while 
BDNF-KO mice exhibited reduced expression of adrenergic receptors [298]. 
Additionally, hypothalamic BDNF increased NE uptake and decreased its evoked release, 
indicating that NET expression may be affected [293]. Finally, BDNF may promote 
catecholamine synthesis, as mutations that lead to reduced BDNF levels also resulted in 
reduced NE synthesis in the hypothalamus [94].  
 As previously mentioned, studies have reported that lesioning catecholaminergic 
projections from the NTS to the PVN results in increased BP [80], supporting the idea 
that these neurons play an inhibitory role on sympathetic outflow from the PVN. Findings 
from our own laboratory also demonstrate that BDNF acting in the PVN, both acutely 
[305] and chronically [102], leads to increased BP. However, the combined effects of 
these two treatments remains understudied. Furthermore, the effects of BDNF 
overexpression in the PVN on catecholamine synthesis and signaling remains poorly 
understood. Therefore, the goal of this study was to examine the combined effect of 
BDNF and DSAP treatment, and how BDNF overexpression in the PVN affects 
expression levels of various adrenergic receptors and NET. Studying the relationship 
between BDNF and NTS NE-ergic projections is important because it could elucidate 
novel mechanisms by which BDNF acting in the PVN causes increased sympathetic 
outflow and subsequent increased BP. Given that hypertensive stimuli such as 
psychological stress increases the expression of BDNF mRNA, BDNF may be an 
important signaling agent in the development and maintenance of hypertension. 
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Therefore, research into BDNF signaling in the CNS is highly important to our 
understanding of the pathogenesis of hypertension. 
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CHAPTER 2: THE EFFECTS OF HYPOTHALAMIC BRAIN-DERIVED 
NEUROTROPHIC FACTOR ON CATECHOLAMINERGIC REGULATION 
OF CARDIOVASCULAR FUNCTION IN THE PARAVENTRICULAR 
NUCLEUS OF THE HYPOTHALAMUS 
 
2.1. Introduction 
Hypertension is a prevalent medical condition affecting approximately 26.4% of 
the global population [184], with only ~82% aware of their condition, and ~52% 
achieving acceptable control of BP [258]. Such high prevalence coupled with inadequate 
control of the symptoms demands that new therapeutic options be explored. One such 
area is the central regulation of the sympathetic nervous system (SNS), as a building 
body of literature suggests that this may play a vital role in most cases of hypertension 
[129]. There are numerous hypothalamic and brainstem nuclei that are involved in central 
regulation of the SNS and the cardiovascular system, most notably the PVN of the 
hypothalamus, and the NTS (Figure 5). The PVN has been shown to influence SNA both 
directly through the IML and indirectly through the RVLM and NTS [21]. The PVN also 
affects BP through alternative pathways, such as synthesis and secretion of important 
hormones in cardiovascular regulation such as corticotrophin releasing hormone (CRH) 
and AVP [35]. There is anatomical evidence showing the NTS has a high density of 
catecholaminergic cells that project to the PVN and that these projections are important 
in sympathetic control of BP and HR [272], likely through inhibition of parvocellular 
PVN neurons [80].  
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Figure 5: The central circuitry involved in sympathetic cardiovascular regulation. 
Rostral ventrolateral medulla (RVLM) neurons increase preganglionic sympathetic 
activity via projections to the intermediolateral (IML) cell column of the 
thoracolumbar spinal cord. RVLM sympathetic activity is modulated via inhibitory 
projections from the caudal ventrolateral medulla (CVLM) or excitatory 
projections from the paraventricular nucleus (PVN) of the hypothalamus. The 
nucleus of the solitary tract (NTS) receives baroreceptor afferents and regulates 
sympathetic outflow from the RVLM via excitatory projections to the CVLM, or 
through inhibitory projections to the PVN. Hypertensive stimuli (e.g. chronic stress 
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or obesity) and BDNF activate PVN sympathoregulatory neurons to increase BP 
Preliminary data from our lab indicates that BDNF may also decrease the PVNs 
sensitivity to hypotensive projections from the NTS. 
 
BDNF is a member of the neurotrophin family that plays a key role in regulating 
neuronal development and survival [16]. It has long been known that BDNF has effects 
on learning and memory [16, 34, 196, 221], and it has recently been shown that BDNF 
may also have effects on cardiovascular function in medullary and hypothalamic nuclei. 
Hypothalamic studies report that BDNF levels in the PVN are significantly elevated in 
response to hypertensive stimuli such as stress [11, 126, 132, 314] and hyperosmolarity 
[11]. Our laboratory has recently published data indicating that both acute injection of 
BDNF and long-term overexpression of BDNF in the PVN result in elevated BP, HR, and 
SNS activity [102, 305]. However, the mechanisms activated by BDNF in the PVN, and 
how they affect NTS catecholaminergic projections to the PVN remain to be investigated. 
Saporin is a highly potent neurotoxin [321] that when conjugated to dopamine beta 
hydroxylase (DBH) is allowed to enter into catecholaminergic neurons [278] and thereby 
selectively destroy only those neurons. Lesioning NTS NE-ergic neurons using DBH-
conjugated saporin (DSAP) has demonstrated that this neuronal population plays an 
inhibitory role on baseline arterial pressure response and cardiovascular acute stress 
response [80].  
Hypothalamic NA-ergic signaling may be regulated by BDNF, since BDNF 
increases NE uptake and decreases its evoked release [293], while also increasing NE 
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concentration in this area [94]. This indicates that BDNF acting in the hypothalamus 
increases NE synthesis while also suppressing NE signaling through two potential 
mechanisms. Chronic overexpression of BDNF mRNA in the PVN could alter the 
expression of a and b adrenergic receptors which are important in the PVN control of BP 
[31, 53, 301], or increase the expression of norepinephrine transporter (NET) which 
would diminish the sensitivity of PVN neurons to NE [293]. b adrenergic receptors are 
believed to play an inhibitory role in PVN activity, since microinjections of b antagonists 
into the PVN causes decreased BP [343] and can increase spontaneous activity of PVN 
sympathoregulatory neurons [301]. The effects of BDNF overexpression in the PVN and 
DSAP injections into the NTS on stress responsiveness have been already studied 
separately in SD rats [80, 101]. However, the underlying mechanisms and potential 
effects of combined treatment remain to be determined. Previous findings from our 
laboratory indicate that BDNF overexpression in the PVN leads to a diminished change 
in MAP in response to acute stressors [101]. Therefore, the goal of the present study is to 
investigate the effects of BDNF signaling in the PVN on NE-ergic projections from the 
NTS. Our hypothesis is that BDNF activates sympathoregulatory PVN neurons in part by 
disabling inhibitory actions of NTS catecholaminergic projections to the PVN by 
decreasing the expression of various subtypes of adrenergic receptors in the PVN. 
2.2. Materials and Methods 
All animal housing, handling, surgical and experimental procedures were 
conducted within an animal care facility accredited by the Association for the Assessment 
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and Accreditation of Laboratory Care International at the University of Vermont, in 
accordance with the USA Public Health Service Policy on Human Care and Use of 
Laboratory Animals and the National Institute of Health’s Guide for the Care and Use of 
Laboratory Animals. Experiments were performed in male Sprague-Dawley (SD) rat 
obtained from Charles River (Saint-Constant, QC, Canada) at 7-9 weeks of age. Rats 
were housed individually with a 12-hour light/dark cycle (lights on at 6:00 am), with free 
access to food (standard chow) and water. All experimental procedures were approved by 
the Institutional Animal Care and Use Committee at the University of Vermont. 
 
2.2.1. Experimental Design 
2.2.1.1. Experiment 1 
The goal of this study was to determine the hypertensive effects of lesioning 
noradrenergic neurons in the NTS and overexpressing BDNF mRNA in the PVN. 
Radiotelemetric transmitters were implanted into the abdominal aorta of 8 to 9 wk old 
Sprague Dawley (SD) rats. After a 2-wk post-operative recovery period, baseline 
parameters were recorded for a week. Following this recording period the rats received 
bilateral PVN injections of adeno-associated viral vector serotype 2 (AAV2) to express 
either green fluorescent protein (AAV2-GFP) or a myc epitope-tagged BDNF fusion 
protein (AAV2-BDNFmyc), and bilateral NTS injections of either phosphate saline 
buffer (PBS) or the neurotoxin DSAP, which is selective to noradrenergic and adrenergic 
neurons. This provided four treatment groups; GFP+PBS (n = 6), GFP+DSAP (n = 7), 
BDNF+PBS (n = 8), and BDNF+DSAP (n = 7). Rats were allowed to recover for 1-wk 
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after the second surgery, after which point there was a 2-wk period of BP recording. 
Responses to acute restraint and water stress were then recorded with a week of recording 
in between stress tests. Animals were euthanized after the water stress and their brain 
tissue was collected following transcardiac perfusion with ice-cold PBS and 4% 
paraformaldehyde. Immunohistochemistry (IHC) was performed on the brain tissue to 
verify the accuracy of the vector and DSAP injection sites. 
 
2.2.1.2. Experiment 2 
 The goal of this experiment was to determine if BDNF overexpression in the PVN 
altered expression of adrenergic receptors and NET in the PVN. Microinjections of 
AAV2 viral vectors expressing either GFP or BDNF mixed with red FluoSphere 
carboxylate-modified microbeads were administered bilaterally into the PVN of SD rats 
at approximately 8 weeks of age. The microbeads allowed for the injected brain tissue to 
be seen when harvesting tissue. After 5 wks, the rats were decapitated under 5% 
isoflurane anesthesia, and the brain was harvested and flash frozen in Tissue Tek 
optimum cutting temperature (O.C.T.) compound (Sakura® Finetek) by placing it in a 
liquid nitrogen chamber. Verification of injections and isolation of the PVN tissue were 
performed using a novel technique which involved sectioning the frozen brain tissue with 
a cryostat until the red microbeads at the PVN injection sites were visible (Figure 6), and 
isolating the injected area of both the left and right PVN using a brain punch tool at a 
depth of around ~1 mm3. Depth of the punch was then confirmed by continued slicing of 
the remaining brain tissue. This brain punch method is an improvement in our laboratory 
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due to increased visibility of injection site as a result of the red microbeads and image 
capture with a portable microscope, which allowed for increased accuracy, precision, and 
accountability. The mRNA collected from these brain punches were assessed by 
quantitative RT-PCR with primers for Adra1a, Adra1b, Adra2a, Adrb1, Adrb2, BDNF, 
NET, and the housekeeping control 18s as described below.  
 
Figure 6. Example of brain punches from SD rats taken with the aid of a cryostat 
and a brain punch tool. (A) Shows a coronal section at the level of the PVN before 
the punch, with both injection sites visible thanks to the red microbeads. (B) Shows 
the same site after ~1 mm3 of tissue including the PVN had been taken on both sides 
using a brain punch tool. 
 
2.2.2. Surgical Procedures 
All surgeries were performed using aseptic techniques under continuous 
isoflurane anesthesia (5% induction, 2% to 3% maintenance) delivered in oxygen. Depth 
of anesthesia was assured by pinching the hind paw to confirm lack of reflex response. 
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For 2 days following each surgery and right before every surgery, rats were administered 
a subcutaneous (sc) injection of 0.4 mL carprofen (5mg/kg/day in 0.4mL). 
 Radiotelemetric transducers (model PA-C40; Data Sciences International, St. 
Paul, MN) were implanted into the descending aorta via a midline abdominal incision. 
The aorta was briefly isolated and occluded, allowing for insertion of the catheter using 
the bent tip of a 21-gauge needle. Surgical glue (3M Vetbound Tissue Adhesive) and a 
nitrocellulose patch were used to secure the catheter in place. The transducer was sutured 
to the abdominal muscle, and the incision was closed in layers.  
 Viral vector, PBS and DSAP, injections involved placing the rats into a 
stereotaxic frame under isoflurane anesthesia. Their skulls were exposed to find the 
bregma, and a cranial window (~ 3 x 4 mm) was created to expose an area of the brain 
surface dorsal to the PVN. Microinjections were then performed using borosilicate glass 
capillary tubes (OD, 1 mm; ID, 0.58 mm; tip diameter, ~25 µm). Stereotaxic coordinates 
for the PVN were 1.8 posterior, 1.7 lateral from the midline, and 7.7 ventral from the 
dura mater. For NTS injections, the head was rotated 30° forward, and a midline incision 
was made over the occipital region. Using the calamus scriptorius as reference the 
coordinates for NTS injections were 0.0 posterior, 0.3 lateral from the midline, and 0.5 
ventral from the dura mater.  
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2.2.3. Microinjections 
2.2.3.1. Viral Vectors 
AAV2 viral vectors were used to express enhanced GFP or myc-conjugated rat 
BDNF (BDNFmyc). Vectors were constructed and packaged by Vector Biolabs 
(Philadelphia, PA). A chicken-β-actin promoter drove the expression of GFP and 
BDNFmyc with human cytomegalovirus enhancer, and a woodchuck post-transcriptional 
regulatory element, which enhanced the expression of transgenes, was present 
downstream of GFP and BDNFmyc. Full efficacy of the BDNFmyc expression driven by 
rat neuron-specific enolase promoter was confirmed previously both in vitro and in vivo 
[187], and BDNF overexpression using the same viral vectors has been shown to 
significantly elevated BP and HR in normotensive rats [102]. Virus stock (1012 viral 
particles/ml; 200 nl/side) were injected over a 5 min period using a pneumatic pico pump 
(World Precision Instruments, Sarasota, FL). After the injections, pipettes were left in 
place for an additional 3 min before being withdrawn.  Viral vector stock solutions used 
in Experiment 2 were diluted (10%) with red FluoSphere carboxylate-modified 
microbeads which allowed for the injected brain tissue to be seen when harvesting. 
 
2.2.3.2. DSAP Injections into the NTS 
DSAP is an immunotoxin that can selectively lesion catecholaminergic neurons 
[80, 227, 289, 368]. DSAP (Advanced Targeting Systems, San Deigo, CA, USA) was 
diluted to a concentration of 0.22 ng nl-1 in 0.1 M sterile phosphate buffered saline (PBS) 
(pH 7.4). Rats in experiment 1 received bilateral NTS injections of DSAP (22 ng in 100 
 52 
nL sterile saline) or PBS (100 nL) delivered over a 5 min period using a pneumatic pico 
pump (World Precision Instruments, Sarasota, FL). 
 
2.2.4. Immunohistochemistry 
 Animals in experiment 1 were anesthetized with 5% isoflurane and perfused with 
400 ml of cold PBS followed by 400 ml of cold 4% paraformaldehyde (PFA) in PBS. 
Brains were postfixed for 2 h in 4% PFA, then stored in 30% sucrose solution at 4°C. 
Coronal sections (40 µm) were cut on a microtome (Thermo Scientific – Microm HM 
450) and mounted on Fisher Superfrost Plus slides. BDNFmyc were detected using the 
primary antibody rabbit anti-Myc (Abcam, 1:200 overnight incubation at 4°C). Neuronal 
markers for noradrenergic neurons were detected using the following primary antibodies: 
mouse anti-Dopamine β Hydroxylase (ms anti-DBH; Millipore, 1:500 overnight 
incubation at 4°C) and rabbit anti-TH (rab anti-TH; Millipore, 1:500 overnight incubation 
at 4°C) to confirm the efficacy of DSAP treatment. Secondary antibodies were Alexa 
Fluor® 488 donkey anti-rabbit (Life Technologies) and Alexa Fluor® 555 donkey anti-
mouse (Life Technologies). Immunofluorescence and GFP were detected with a 
fluorescent microscope (Nikon Eclipse 50i, Micro Video Instruments, Inc. Avon, MA). 
Rat brains with accurate PVN injections fluoresced bilaterally on the area of the PVN as 
seen in a coronal section, while NTS injections were accurate if they fluoresced in the 
dorsomedial portion of the medulla as seen in a horizontal section (Figure 7). 
Microinjections of DSAP significantly reduced the number of DBH-positive neurons in 
the NTS (Figure 7). Previous studied have reported that low dose of DSAP 
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microinjections (22 ng per side) caused an 87% reduction while a high dose (27 ng per 
side) caused a 97% reduction [80]. A low dose of DSAP was chosen for this study due to 
the non-specific cell toxicity observed from high doses of DSAP [80]. 
 
 
Figure 7. Confirmation of injection sites for the various treatments using IHC. PVN 
injections appear as expected, with GFP stained cells fluorescing brightly, and myc-
tagged cells fluorescing a normal amount. NTS injections demonstrate that DSAP 
treatment substantially reduces the amount of cell bodies, which are primarily 
catecholaminergic. 
PBS DSAP
Anti-­‐DBH Anti-­‐DBH
NTS NTS
GFP Anti-­‐myc	  Ab
PVN PVN3V
3V
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2.2.5. Acute Stress Procedures 
 Acute stress procedures were performed between 8 am and 12 pm after obtaining 
baseline BP and HR recordings for a minimum of 30 min. For water stress, rats were 
placed into standard rat cages filled with 1 cm of room temperature (~25°C) water for 15 
min. Restraint stress was performed by placing the rats in a cylindrical plastic restrainer 
for 60 min. After animals were returned to their home cages, BP and HR were recorded 
for an additional 30 min for water stress and 60 min for restraint stress as a recovery 
period. BP and HR data were exported with a 1 min moving average from continuously 
recorded BP data, with baseline values calculated by averaging the baseline period after 
physical activity-related peaks from BP and HR datasets were removed. Average BP and 
HR changes from baseline (during stress and after stress), as well as amplitude and time 
delay of peak responses, were calculated. 
 
2.2.6. Analysis of Radiotelemetry Data 
BP and HR radiotelemetry data were analyzed using Dataquest A.R.T Analysis 
software (Data Sciences International). Data were recorded every 10 min and 15 s, and 
data collected between 8 am and 4 pm were averaged to calculate daytime values, 
whereas data collected between 8 pm and 4 am were averaged to calculate nighttime 
values. The telemetry system also assessed spontaneous physical activity of animals 
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based on variations in signal strength from the transmitter and were expressed in arbitrary 
units.   
 
2.2.7. Real-time RT-PCR 
 Expression of BDNF, α1a, α1b, α2a, b1, and b2 adrenergic receptors, and NE 
transporter (NET) and 18s RNA were analyzed using quantitative real-time RT-PCV 
using specific oligonucleotide primers and Taqman probes. Total RNA was extracted 
from ~1 mm3 brain punches containing the PVN submerged in Trizol (the two sides were 
separated from each animal) using the RNeasy Mini Kit (Qiagen, Valencia, CA). Tissue 
was first ground with chloroform, then centrifuged, then the upper aqueous layer was 
removed. RNA samples were treated with an RNase-free DNase Set (Qiagen) to remove 
genomic DNA and were used to create cDNA with a high capacity of cDNA archive kit 
(Applied Biosystems High-Capacity cDNA RT kit) according to the manufacturer’s 
instructions and stored at -20°C. cDNA samples were then submitted to the University of 
Vermont DNA Core for Taqman using the following primers: 18s, BDNF, Adra1a, 
Adra1b, Adra2a, Adrb1, Adrb2, and mSlc6a2. RT-PCR was run using Applied 
Biosystems, and control reactions containing no template were run for each plate. 
 
2.2.8. Statistical Analysis 
Data were analyzed by Student’s t-test, one-way ANOVA, or two-way repeated-
measures ANOVA, and, if the main effect was significant, Tukey’s post hoc test was 
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applied to determine individual differences between means. Results are expressed as 
means ± SE, and a value of P < 0.05 was considered significant. 
 
2.3. Results 
 
2.3.1. Effects of BDNF overexpression and DSAP injections on baseline 
cardiovascular parameters 
Radiotelemetric MAP and HR data collected after injections during non-stress 
baseline periods showed that both AAV2-BDNFmyc injections into the PVN and DSAP 
injections into the NTS significantly increased daytime MAP and HR (Figure 8). The 
MAP increase observed in BDNF treated rats was also seen in DSAP treated rats, 
although combined treatment (BDNF+DSAP) produced no additional hypertensive 
effects (Figure 8A). DSAP treatment increased HR in both the GFP and the BDNF group, 
although there was a more pronounced change in HR in the GFP rats then in the BDNF 
rats, though this change was not statistically significant (Figure 8B). Nighttime MAP and 
HR data generally show the same trends as the daytime data, although there was a 
noticeably increased change in HR (Figure 8D) in DSAP treated rats. 
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Figure 8. Changes in baseline MAP and HR in response to BDNF or DSAP 
treatment. (A) DSAP injection significantly increased MAP within the GFP group, 
but had no additional hypertensive effect in BDNF rats. (B) Heart rate was elevated 
by DSAP treatment both in GFP and BDNF rats, although this effect seemed to be 
greater in GFP rats. (C) DSAP treatment elevated nighttime MAP in the 
GFP+DSAP. (D) DSAP treatment elevated nighttime HR relative to the daytime 
HR, although this effect seemed to be greater in the GFP rats. 2-way repeated 
measures of ANOVA; *p<0.05 for effects on both BDNF and DSAP + interaction. 
Postoperative recovery period and stress periods were omitted. 
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2.3.2. Experiment 1 Acute Stress Radiotelemetry Results 
Results from this study demonstrate that BDNF treatment reduced MAP and HR 
responses to stress, confirming previous findings from our laboratory (Figure 9 & 10). 
This trend was seen in both the 60 min restraint stress and the 15 min water stress, 
although the BDNF effects on stress response during the water stress were most 
pronounced (Figure 9 & 10). Lesioning NTS NA-ergic projections with DSAP did not 
significantly affect MAP response to stress [80]. However, within the GFP treatment 
group, DSAP treatment significantly reduced the initial HR response to restraint and 
water stress (Figure 9  & 10). The sudden spike in HR seen in the restraint stress at 60 
min is due to the termination of the stress test and removal of the animal from the 
restraint tube (Figure 9).  
 
 
Figure 9. BDNF injections appear to decrease the MAP response to restraint stress. 
In the GFP treatment group, DSAP injection significantly decreased the initial HR 
response to restraint stress. 
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Figure 10. BDNF injections appear to decrease the initial MAP response to water 
stress. In the GFP treatment group, DSAP injection significantly decreased the 
initial HR response to water stress. 
 
2.3.3. Experiment 1 Body Weight and Food Intake 
Rats subjected to PVN overexpression of BDNF demonstrated significantly 
reduced increase in body weights compared with GFP rats (Figure 11). Food intake was 
reduced in BDNF+PBS rats compared with rats in the GFP+PBS group. DSAP 
significantly increased food intake in rats subject to GFP overexpression in the PVN, 
whereas DSAP had no effect in rats subject to BDNF overexpression (Figure 11). 
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Figure 11. BDNF treatment significantly reduced the body weight gain compared to 
GFP controls. DSAP treatment significantly elevated daily food intake, but only in 
the GFP treatment group. 
 
2.3.4. BDNF Effects on Catecholaminergic Signaling between the PVN and the NTS 
 Real-time RT-PCR analysis on PVN tissue samples from experiment 2 indicated 
that BDNF treatment significantly reduced the expression of b1 adrenergic receptor 
mRNA expression [2−ΔΔCt values compared with 18s RNA in the BDNF group were 0.62 
± 0.03 (b1) normalized to 2−ΔΔCt values of the GFP group] (Figure 12A-E). In contrast, 
mRNA expression of a1a, a1b, a2a, and b2 adrenergic receptors were unaffected by 
BDNF [2−ΔΔCt values compared with 18s RNA in the BDNF group were 0.87 ± 0.09 
(a1a), 0.74 ± 0.04 (a1b), 0.86 ± 0.11 (a2a), and 0.79 ± 0.10 (b2) relative to the GFP 
group]. Real-time RT-PCR analysis on NTS tissue samples indicated that BDNF 
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treatment significantly increased the expression of TH and DBH mRNA expression 
[2−ΔΔCt values compared with 18s RNA in the BDNF group were 1.89 ± 0.23 (TH), and 
1.81 ± 0.19 (DBH) relative to the GFP group] (Figure 12F-G). 
 
 
Figure 12. Expression of (A) a1a, (B) a1b, (C) a2a, (D) b1, and (E) b2 adrenergic 
receptors in the PVN as well as (F) TH and (G) DBH in the NTS compared with 18s 
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mRNA levels using the 2−ΔΔCt method in GFP (n = 7) and BDNF (n = 6) animals 
from experiment 2. Results are represented as means ± SE normalized to the GFP 
group. *p<0.05 for differences between GFP and BDNF groups. 
2.4. Discussion 
In this study, we demonstrated for the first time the combined cardiovascular 
effects of BDNF overexpression in the PVN and lesioning of NE neurons in the NTS. 
Microinjections of AAV2-BDNFmyc into the PVN significantly elevated BP and HR 
under baseline conditions and diminished BP and HR responses to stress, as shown in 
previous publications from our laboratory [102, 305]. Microinjections of DSAP into the 
NTS resulted in increased baseline BP and HR and diminished HR response to acute 
stress in the GFP group. However, combined treatment of BDNF and DSAP had no 
additional hypertensive effects under baseline conditions. This was surprising given that 
BDNF injections in the PVN caused an increase in the expression of TH and DBH in the 
NTS, which indicates an increase in the activity level of these neurons. Lesioning these 
neurons in BDNF treated rats should in theory result in a dramatic increase in BP, yet no 
such trend was observed. We hypothesized that this was due to a decreased sensitivity to 
NE-ergic signals caused by a reduced expression of adrenergic receptors in the PVN. In 
line with this hypothesis, RT-PCR analysis of adrenergic receptor expression following 
BDNF treatment revealed a significant downregulation of b1 receptors in BDNF rats. 
Collectively, these data suggest a novel role for BDNF in cardiovascular control by 
regulating catecholaminergic signaling between the PVN and the NTS. 
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2.4.1. The Role of BDNF in Central Blood Pressure Regulation 
There are numerous reports indicating that BDNF is involved in sympathetic 
regulation of BP. BDNF expression in the PVN significantly increases in response to 
hypertensive stimuli such as stress and hyperosmolarity [11, 132, 314, 315], indicating 
that BDNF signaling in the PVN may increase BP. Additionally, microinjections of 
BDNF into the NTS caused a dose-dependent increase in MAP, HR and SNA while 
microinjections of an anti-BDNF antibody or the tyrosine kinase inhibitor K252a 
achieved the opposite effect, indicating that BDNF signaling in the NTS plays a tonic 
role in regulating cardiovascular function [60]. Numerous studies have shown that the 
NE/E projections to the PVN are inhibitory in nature and therefore lower BP under 
baseline conditions [78, 80, 329]. Lesioning NTS NE-ergic neurons with DSAP has been 
shown to cause an increase in baseline BP and HR [80]. However, the effect of BDNF 
overexpression in the PVN on NTS NE/E projections to the PVN remain understudied. 
 Recent work from our laboratory and others has begun the investigation of what 
role BDNF has in PVN-mediated BP regulation. Prior studies indicate that AT1R 
activation is a major mechanism in the stimulation of PVN sympathoregulatory neurons 
[79], and may play a mediatory role in stress-induced BP responses [46, 55, 81]. Since 
BDNF mRNA levels are also increased in the PVN following similar stimuli, we tested 
the hypothesis that elevated BDNF increased BP through a AngII signaling-dependent 
manner. Overexpression of BDNF mRNA in the PVN resulted in increased BP and HR 
under baseline conditions, and reduced the MAP and HR response to stress [102]. While 
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BDNF treatment had no effect on angiotensin, ACE, or ACE2 mRNA levels in the PVN, 
it was shown that BDNF upregulated AT1R mRNA by ~80% [102]. Results from another 
study demonstrate that acute injections of BDNF into the PVN cause an increase in BP 
and HR, an effect which was attenuated by subsequent injection of the AT1R antagonist 
losartan [305]. However, in both studies inhibition of AT1Rs did not completely abolish 
the BP and HR response to BDNF, indicating that other signaling mechanisms may be 
involved. 
 
2.4.2. BDNF-Mediated Alterations in Central Catecholaminergic Signaling 
 There are a limited number of brain regions that synthesize NE and E, and these 
regions are all involved in cardiovascular regulation. One of these regions comprised of 
A2 NE-ergic and C2 E-ergic neurons is the NTS [74, 304] which is believed to tonically 
inhibit brain regions that generally increase BP such as the PVN [78]. Lesioning or 
silencing these neurons has been shown to result in increased BP [80, 96], although it is 
important to note that other studies report that silencing or lesioning these neurons has no 
effect on baseline MAP [166, 167, 330]. In the PVN, catecholaminergic projections from 
the RVLM [26] and stimulation of a1 adrenergic receptors [53] increase the excitability 
of sympathoregulatory neurons through enhancing glutamatergic inputs and reducing 
GABA release. On the other hand, both a2 [133] and b [3, 301, 343, 356] adrenergic play 
an inhibitory role on PVN activity, although there are conflicting reports on the role of 
a2 receptors claiming that it has no effect on PVN activity [31]. Additionally, simulation 
of a1 and a2 adrenergic receptors in the PVN leads to increased plasma AVP [351] and 
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ACTH [73], indicating that catecholaminergic projections also influence PVN 
neuroendocrine regulation of BP. Catecholaminergic projections to the PVN may also 
mediate acute stress response, as lesioning these neurons with DSAP lead to attenuation 
of ACTH and corticosterone response to acute stress [111]. However, the effects of 
BDNF on the NTS catecholaminergic projections to the PVN are currently understudied. 
In this study, we looked at how BDNF affects catecholaminergic signaling in the 
PVN. Independently, overexpressing BDNF in the PVN and lesioning NE-ergic neurons 
in the NTS resulted in increased baseline MAP and BP, which is consistent with findings 
from our laboratory [102, 305] and others [80, 101]. However, lesioning NTS NE/E 
projections to the PVN had no additional hypertensive effect on BDNF treated rats 
despite increased catecholamine synthesis in the NTS of non-lesioned rats. One potential 
explanation for the increased NTS activity is that BDNF-mediated BP elevation results in 
an increased baroreceptor input, which in turn stimulates NTS NE-ergic neurons. 
However, BDNF overexpression in the PVN somehow interferes with the communication 
between the NTS and the PVN. We hypothesized that this was due to decreased 
expression of a1a and a1b adrenergic receptors, decreased expression of b1 or b2 
adrenergic receptors, and/or increased expression of NET. The data presented here 
indicates that downregulation of b1 adrenergic receptors in the PVN may contribute to 
this interference, which agrees with studies demonstrating the inhibitory role they play on 
sympathoregulatory PVN neurons [3, 301, 343, 356]. One such study showed that 
microinjections of the b-adrenoceptor antagonist propranolol into the PVN caused an 
increase in spontaneous electrical activity of catecholaminergic neurons and prevented 
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the inhibitory actions of NTS noradrenergic projections to the PVN [301]. Further 
investigation of how BDNF affects adrenergic receptor expression would be necessary 
before any definitive claims could be made though. Additionally, while BDNF+DSAP 
had no synergistic effect on baseline MAP, it did have a synergistic effect on baseline 
HR. This indicates that that the effects of BDNF overexpression in the PVN on HR are 
potentially mediated through different pathways than BP. 
 
2.4.3. Effects of BDNF and DSAP on Acute Stress Response 
BDNF can potentially modulate stress responsiveness in the PVN in numerous 
ways including neuronal plasticity, neurite outgrowth [249], stimulation of CRH 
synthesis [126], and central angiotensin signaling [102]. In this study, we have shown 
that catecholaminergic signaling may not play a significant role in stress responsiveness 
in the PVN. In accordance with prior research from our laboratory, we tested whether 
long-term overexpression of BDNF in the PVN would affect the amplitude of 
cardiovascular response to acute stressor, with the added element of lesioning NTS NE/E 
neurons. In accordance with prior publications from our laboratory [102], BDNF 
treatment caused a reduction in the pressor response to acute stress. DSAP treatment had 
no substantial effect on MAP response to acute stress, although it caused a significant 
decrease in the initial HR response. Interestingly the results from our stress tests 
contradicted findings from other DSAP studies, which found that DSAP injection 
increased the MAP response to stress [80]. There was no significant difference between 
BDNF and combined treatment (BDNF+DSAP), which demonstrates the insubstantial 
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role that NE-ergic signaling appears to play in stress responsiveness. While NTS NE-
ergic neurons were successfully lesioned in both studies, we also performed injections 
into the PVN which may cause alterations in stress responsiveness. The reduced pressor 
response seen in BDNF treated rats may be due to significantly higher baseline BP and a 
ceiling effect, and it is important to note that absolute BP was still considerably higher 
than in GFP treated rats. An alternative theory is that long-term elevation in BDNF 
concentrations in the PVN of BDNF rats induces neuronal plasticity and adaptive 
mechanisms leading to reduced stress responsiveness. This may also explain the reduced 
cardiovascular response seen in animals repeatedly subjected to the same type of stressor 
[63].  
  
2.5. Conclusions 
 In conclusion, our findings indicate that BDNF acting in the PVN plays a major 
role in the central regulation of BP and HR, and suggests a novel mechanism by which 
BDNF modulates NE-ergic input from the NTS to the PVN. Our findings from the DSAP 
study demonstrate that lesioning NTS NE-ergic neurons results in increased BP in 
correlation with previous studies on the subject [80, 291]. However, combined treatment 
of BDNF and DSAP had no additional hypertensive effects, indicating that BDNF 
interrupts catecholaminergic signaling. Downregulation of b1 adrenergic receptors in the 
PVN, which play an inhibitory role on PVN neurons [301], was shown in BDNF treated 
rats, indicating that these receptors may mediate the diminished DSAP effects. The 
insights gained through studying how BDNF in the PVN affects catecholaminergic 
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signaling in the NTS may have important implications for understanding hypertensive 
response to various stimuli that influence BDNF levels in the PVN including stress [126, 
132, 314], exercise [251], aging [313], high salt diet [11, 58, 135], and obesity [355].  
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CHAPTER 3: SIGNIFICANCE OF FINDINGS 
3.1. Review of Hypertension and the Importance of Sympathetic Cardiovascular 
Regulation 
 Patients suffering from hypertension are at an increased risk for life-threatening 
cardiovascular conditions such as coronary heart disease, stroke, and heart failure. Some 
of the most common risk factors for hypertension are stress [90], high salt diet [382], and 
obesity [178]. Hypertension is an incredibly prevalent condition, affecting approximately 
29.1% of the adult US population, with ~82% of people being aware of their condition 
and ~52% achieving acceptable control of BP [258]. There are several treatment options 
that help lower BP by targeting the heart or the vasculature, but only a few options that 
target the underlying problem. Recent research has shown that elevated SNA is present in 
most cases of hypertension [306], and therefore novel treatment options that address this 
issue may be of substantial help in combatting this condition. The handful of SNA 
targeting hypertension treatments available currently have been relatively successful. 
Surgical interventions such as the catheter-based radiofrequency ablation of the renal 
sympathetic nerves, and baroreflex activation have both showed promise in clinical trials 
[194]. Therefore, it is important to thoroughly research the central regulatory nuclei of 
sympathetic outflow to more completely understand the cause and mechanisms of 
sympathetic related hypertension. 
 Manipulation of activity in the central cardioregulatory nuclei has been shown to 
affect BP both during baseline periods and in response to stress. Excitation of the RVLM 
produces increased sympathetic outflow and BP, while inhibition causes decreased 
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sympathetic outflow and BP [78]. Hypertensive stimuli such as stress may lead to 
increased RVLM activity which mediates the BP response to stress, as microinjections of 
CRH into the PVN caused an increase in RVLM neuronal activity [119]. Silencing or 
lesioning NTS NE/E neurons, which project to the RVLM and PVN to inhibit their 
activity under normal conditions [6, 80], has been shown to increase BP in numerous 
studies [80, 101]. Projections from the PVN to extrahypothalamic and spinal cord 
cardioregulatory nuclei tend to promote increased BP [78, 282, 309]. Lesioning the 
parvocellular PVN neurons, which are involved in mediating sympathetic outflow from 
the brain, has been shown to result in reflex reduction of RSNA [136, 220]. Furthermore, 
chronic stress causes significant biochemical changes in the PVN to increase excitability 
via reducing expression of GABAA receptors [71, 352] and increasing expression of 
NMDA receptors [114]. While the NE-ergic projections from the NTS to the PVN are 
known to be inhibitory in nature, the effect of PVN neurons on the NTS, and how this 
communication is affected is a currently understudied area. 
 In this study, we have shown how BDNF overexpression in PVN and lesioning 
NE-ergic NTS neurons with DSAP affects sympathetic cardiovascular regulation. As 
expected from previous research [80, 102], increased BP was seen following BDNF 
overexpression in the PVN and DSAP lesioning of the NTS. Interestingly, we found that 
combined effect of BDNF and DSAP treatment had no additional hypertensive effects, 
indicating that in the BDNF group the inhibitory projections from the NTS to the PVN 
did not affect sympathetic outflow. As a result, we hypothesized that this was due to 
BDNF causing a decreased expression of adrenergic receptors in the PVN as a 
 71 
mechanism for decreased sensitivity to NE-ergic NTS projections. We found that BDNF 
treated rats exhibited a significant downregulation of b1 adrenergic receptors, which may 
be a mechanism involved in the mediation of the response to DSAP treatment. 
 
3.2. Why Study BDNF? 
 BDNF is a neurotrophin that is involved in synaptic strengthening, neuronal cell 
growth, and differentiation both in developing and adult neurons [157]. In addition to 
these general neurotrophin traits, BDNF is also involved in learning and memory, 
specifically the conversion of short-term memories into long-term memories [14, 223, 
284] and in the facilitation of LTP [223, 269]. Recent research has also demonstrated that 
BDNF may play an important role in central regulation of the cardiovascular system, as 
there is an increased BDNF mRNA expression in the PVN following both acute and 
chronic stress [50, 314]. Furthermore, immobilization stress induces rapid increases in 
BDNF mRNA expression in the hippocampus, hypothalamus, and pituitary [125, 230, 
285]. These findings could be explained by reflex increase in BDNF mRNA in response 
to stress in order to induce plastic changes in the circuitry to better prepare the animal for 
future stressors. In this study and in prior studies from our laboratory we have shown that 
chronic overexpression of BDNF in the PVN leads to decreased stress responsiveness 
[102], which may also explain observations that animals repeatedly subjected to the same 
type of stressor have a decline in cardiovascular responsiveness [63]. The mechanisms 
through which BDNF affects central cardiovascular regulation could be mediated through 
catecholaminergic signaling, as BDNF treated rats had a dose-dependent increase in TH-
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positive neurons, dopamine content, and dopamine uptake activity [161]. In this study, 
we found that BDNF overexpression in the PVN resulted in increased catecholamine 
synthesis in the NTS with reduced sensitivity to NE-ergic projections in the PVN, and 
showed that this was due to talk about RT-PCR findings.  
 Overexpression of BDNF in the PVN is a useful model for hypertension for a 
number of reasons. Some of the most common risk factors for the development of 
hypertension, such as stress and obesity, are associated with overexpression of BDNF. 
Chronic stress has been shown to increase BDNF expression in the BNST [132] and in 
the PVN [126, 132, 313, 314]. Increased BDNF expression in the PVN is linked to 
reduced body weight and food intake [355] and heterozygous BDNF mice exhibited 
significantly increased body weight and food intake [226]. The effects of stress on BDNF 
mRNA expression indicates a positive correlation between BDNF levels and BP, while 
the effects of BDNF on body weight indicate a negative correlation. Regardless, 
alterations in BDNF signaling may be an important factor in the development of 
hypertension. In fact, research from our laboratory has shown that chronic overexpression 
of BDNF in the PVN leads to increased baseline BP just like what is seen in hypertension 
[102, 305]. This is a useful experimental model for studying hypertension because it is 
linked to some of the most common hypertensive risk factors, is easy to induce in any rat 
model, and may shed light on novel types of hypertension related more exclusively to 
increased BDNF. Hyperactivity of the SNS is implicated as an underlying cause for 
hypertension, and major changes in the central circuitry regulating sympathetic outflow 
may be explained by plasticity promoted by BDNF overexpression. 
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3.3. Potential Applications of Findings 
 As mentioned above, findings from this study and others indicates that BDNF 
overexpression in the PVN could be a useful model for hypertension in animal models 
[102, 305]. Since BDNF mRNA expression is elevated in response to hypertensive 
stimuli such as stress [126, 132, 313, 314] and hyperosmolarity [11], it is reasonable to 
assume the model resembles certain naturally occurring cases of hypertension in humans. 
As such, studying exactly how BDNF affects central regulation of cardiovascular 
regulation is important as it may shed light on cellular pathology of this prevalent 
condition. On a related note, increasing hypothalamic BDNF levels using gene therapy 
has recently emerged as a potential therapeutic option for obesity and diabetes [49, 252]. 
However, findings from our lab demonstrate that this would also cause an increase in BP, 
and therefore such therapeutic approaches may have unwanted cardiovascular side 
effects.  
 Additionally, BDNF and TrkB signaling in the PVN and other relevant 
cardioregulatory nuclei could prove to be a novel pharmacological target in the treatment 
of hypertension. For example, homozygous BDNF mutations in the PVN cause a 
profound reduction of NE concentration in the hypothalamus [94], which indicates that 
antagonizing BDNF expression will impair sympathetic outflow and thereby lower BP. 
Analysis of TrkB isoforms in stroke-prone SHR rats revealed that truncated TrkB.T1 was 
significantly upregulated [113], suggesting that BDNF signaling may be disrupted during 
hypertension. Furthermore, the highest levels of BDNF concentration in the adult 
mammalian brain are found in the hippocampus and hypothalamus [181], suggesting that 
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systemic application of centrally acting anti-BDNF drugs would be reasonably specific to 
the target tissue. One major problem for using BDNF-targeted drugs is that BDNF does 
not cross the BBB [267], meaning that the drugs would not be able to reach their target 
tissue (hypothalamus). However, newer research into transmigrating BBB-impermeable 
drugs across the BBB using magnetic nanoparticles suggests that such a drug carrier 
could assist systemic BDNF in crossing the BBB [275]. Similar techniques could be used 
to transport TrkB antagonists resembling BDNF in structure to the hypothalamus to 
reduce BP in hypertensive patients. 
 There are a handful of TrkB antagonists that have been used to study BDNF 
signaling, including the non-specific TrkB antagonist K252a and the highly selective 
TrkB antagonist [N2-2-2-oxoazepan-3-yl amino] carbonyl phenyl benzo (b)thiophene-2-
carboamide (ANA-12). Research has showed that injections of K252a cause a significant 
drop in MAP and HR, which is the expected result given that they also found that  BDNF 
injections into the NTS elevate MAP and HR [60]. Baroreflex sensitivity in the NTS is 
reported to diminish following chronic heart failure, and injections of BDNF into the 
NTS of CHF rats caused a dose-dependent depressor and sympatho-inhibitory effect 
while ANA-12 achieved the opposite [32]. Interestingly these two studies contradict one 
another with regards to BDNF-mediated effects on NTS BP regulation, with one 
reporting that inhibition of TrkB receptors in the NTS causes reduced MAP and HR 
while the other reports that it increases MAP and HR. This difference could be due to 
different TrkB antagonists used, or o the fact that they experimented on different animal 
models that might have varying responses to the same treatment. In either case, our 
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results appear to agree with the K252a study, as BDNF injections into the PVN lead to 
decreased NTS activity and therefore increased MAP and HR under baseline conditions. 
However, it would be interesting to perform injections of BDNF injections directly into 
the NTS to investigate which claim is correct. 
 
3.4. Problems with Experiment and Future Directions 
 Recent work in our laboratory has discussed the effects of BDNF on angiotensin-
ergic signaling [102, 305]. Microinjections of viral vectors expressing BDNF mRNA into 
the PVN resulted in upregulation of AT1R mRNA expression [102]. Study of the short 
term effects of BDNF revealed that injections of the AT1R antagonist losartan into the 
PVN attenuated the increased MAP seen following BDNF injections [305]. In this study 
we examined the effects of BDNF on catecholaminergic signaling, analyzing the effects 
of BDNF overexpression in the PVN of rats with or without lesioned NE-ergic neurons in 
the NTS, and on the expression of various adrenergic receptors in the PVN. In agreement 
with previous papers, we found MAP and HR increased in response to BDNF 
overexpression in the PVN [102] and DSAP injections in the NTS [80], although there 
was no synergistic effects of combined treatment. Additionally, we found that BDNF 
increases catecholamine synthesis in the NTS while also reducing sensitivity to these 
signals in the PVN. This effect may be caused by downregulation of b1 receptors in the 
PVN, which play an inhibitory role on PVN activity under normal physiological 
conditions [3, 301, 343, 356]. Future studies on BDNF effects on the central nuclei 
involved in cardiovascular regulation could focus on the effects in GABAergic and 
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glutamatergic signaling. Most studies report that BDNF enhances NMDA-mediated 
glutamatergic transmission [204, 205]. There is some controversy found in the literature 
on this subject, as electrophysiological studies of BDNF modulation of glutamatergic 
AMPA signaling in the NTS found that BDNF strongly inhibits AMPA-mediated 
currents in the NTS [25]. Heterozygous BDNF mice consistently exhibit decreased 
function of the GABAergic system, as reduced BDNF expression results in reduced 
GABAergic terminals [188] and GABA release in the visual cortex is less efficient [2]. 
Regardless of the controversial findings in this area, studying the effects of BDNF 
mRNA overexpression on glutamatergic signaling in the PVN would further our 
understanding of how BDNF affects central cardiovascular regulation. 
 Future studies could also focus on developing central TrkB receptor antagonists 
as a therapeutic option for hypertension. Magnetic nanoparticles have most commonly 
been used in the delivery of anti-cancer drugs [10], and research shows that using these 
drug carriers for BDNF can be an effective treatment strategy for drug addiction [275]. 
However, the effect of magnetic nanoparticle transported BDNF or TrkB antagonists 
across the BBB on BP regulation has not yet been studied.  
 In experiment 2, I used a novel technique to increase the accuracy of PVN tissue 
collection. Despite these efforts, only 2 PVN tissue samples indicated measurable 
increases in BDNF mRNA in response to AAV2-BDNF vector injections. This was in 
contrast with our previous study where both BDNF mRNA and protein were significantly 
upregulated in the PVN of AAV2-BDNF-injected rats [102]. A potential explanation for 
this is that the isolated PVN tissue samples did not overlap accurately with the volume of 
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tissue affected by the vector injections. Thus, further improvements in the accuracy will 
be needed for future studies. However, even without significant BDNF mRNA increases 
in the BDNF group, we still found a significant decrease in b1 receptor mRNA 
expression, which may have been caused by BDNF diffusing into the isolated tissue 
sample from the proximal injection site where neurons overexpressed BDNF. 
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